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1. INTRODUCTION
1.1. Innate and adaptive immunity at epithelial surfaces 
The skin and mucosal surfaces represent large and vulnerable interfaces between the host 
and a potentially hostile environment and a competent immune system is essential to 
survival. In vertebrates the immune system consists of two arms - the innate (natural) and 
the adaptive (acquired) immune system (1). The former is evolutionary ancient, rapid but 
has limited antigen specificity. It has no memory function and its efficiency does not 
improve during a response (2). It includes humoral or soluble components like the highly 
potent complement system, primarily active against extracellular pathogens; type 1 
interferons (IFN) produced by virusinfected cells, inhibiting further spread of intracellular 
pathogens and substances with non-specific antimicrobial activity, such as lysozyme and 
antimicrobial peptides (AMP), secreted on epithelial surfaces (2). The cellular components 
of the innate immune system efficiently capture and destroy invading pathogens. They 
include short-lived granulocytes which kill microbes through phagocytosis and secretion of 
AMPs (neutrophils) or through release cytotoxic granules contained in their cytoplasm 
(eosinophils and basophils) (1; 2). Natural killer (NK) cells recognize virusinfected cells and 
kill them through cytotoxic granzyme and perforin (3). Macrophages and dendritic cells 
(DCs) represent a particular subset termed antigen presenting cells (APCs). These cells also 
eliminate pathogens but have a vital additional role in alerting the adaptive immune system. 
The adaptive immune system consists of T and B lymphocytes. This 
phylogenetically younger part of the immune system is capable of mounting highly specific 
responses, but is temporally delayed. Lymphocytes are primarily activated through clonally 
distributed receptors that are highly antigen specific. Development of T cell receptors (TCR) 
and B-cell receptors (BCR), involves specialized DNA rearrangements, through 
recombination from preexisting V(D)J gene segments (4). This process is controlled by the 
activitiy of recombination activation genes (RAG), which allow the generation of up to 1015 
different antigen specific receptors (1). The system improves in both quality and quantity 
during an immune response through mechanisms involving clonal selection and expansion. 
Additionally, it maintains a pool of memory T and B cells after the initial immune response 
has subsided, thus generating immunological memory, important for a faster and more 
robust recall response (5; 6).  
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The BCR is surface-bound immunoglobulin that recognizes native antigen, derived 
from protein, polysaccharide or lipids. B cells may be activated through engagement of the 
BCR but need T-cell help in order to generate an effective antibody response. Activated B 
cells differentiate into antibody-producing cells, called plasma cells. Antibodies are soluble 
immunoglobulins that are secreted from plasma cells. Antibodies that bind to microbial 
surface antigens mediate killing of microbes by complement activation or by enhanced 
phagocytotic activity of neutrophils, macrophages and DCs (7).  
The TCR can only recognize and bind antigen that is presented as immunogenic 
peptides in the context of major histocompatibility complex (MHC)-I or MHC-II molecules 
by APCs (7). All nucleated cells in the organism express MHC class I molecules, which are 
recognized by CD8+ T cells, also called cytotoxic T lymphocytes (CTLs). CTLs are 
particularly important in defence against viral infections. They recognize target cells that 
express virus-derived peptide on MHC-I molecules and kill them via the cytotoxic 
molecules granzyme B and perforin, thus limiting spread of the infection (7). Professional 
APCs also constitutively express MHC class II, specialized for presenting processed 
peptides to cognate CD4+ T helper (TH) cells. 
The skin and the mucosal tissues are populated both by cells of the innate immune 
system, as well as effector T and B cells. T and B cells enter the skin or mucosa after having 
been activated by APCs in regional secondary lymphoid tissue, like lymph nodes. 
Secondary lymphoid tissues represent so-called inductive sites, i.e. the locations where 
adaptive immune responses are initiated.  The microanatomy of these structures ensures that 
immune cells from peripheral organs and blood are brought together in close proximity in 
order to exchange information about a potential threat to the organism. The gut mucosa 
contains constitutive lymphoid aggregates functioning as inductive sites (the Peyer’s 
patches, multiple isolated lymphoid follicles and the appendix), and together with 
mesenteric lymph nodes these structures are collectively described as mucosa associated 
lymphoid tissue (MALT) (8). MALT in the airway mucosa consists of organized lymphoid 
tissue in the upper airways, i.e. Waldeyer’s ring and nasal associated lymphoid tissue 
(NALT) and draining lymph nodes along the respiratory tract. The central airways also 
harbour bronchus associated lymphoid tissue (BALT) under certain conditions (see below) 
but the function of these structures in humans is poorly understood.  
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1.2. Immunobiology of antigen presenting cells 
1.2.1. Dendritic cells 
 
APCs are defined as cells being able to present antigen to T cells. They are characterized by 
the expression of MHC-II molecules and include B cells, macrophages and DCs. The most 
important and the best described professional APC population are the DCs, which possess 
the unique ability to induce immune responses in naïve T cells (9; 10). Steinman and Cohn 
first described DCs in 1973, when they discovered cells with long branch-like extensions 
(from Greek déndron, “tree”), in lymphoid tissue (11). The development of long dendrites 
in their mature form creates a large surface at which communication with T cells may take 
place. DCs are decision-makers, determining whether or not to initiate an adaptive immune 
response. The molecular interactions between the DC and the T cells recognizing the 
peptide it presents, determine the magnitude and quality of that immune response (10). 
Thus, these cells fulfil the vital task of bridging the innate and adaptive immune systems. 
In addition to their role as APCs, DCs produce cytokines which allow them to exert 
effector cell functions. A subset of DCs called plasmacytoid DCs (pDCs) produce large 
amounts of IFN-, important in anti-viral defence (12). Also, DCs have recently been found 
to function as NK cells, inducing apoptosis in target cells in cancer as well as in infection 
with the intracellular bacterium Listeria monocytogenes (13; 14). 
 
1.2.2. Activation and maturation of DCs  
DCs are present in blood and all tissues but accumulate in strategically important locations: 
the interfaces between the host and the environment like skin and mucosae. Here, under 
steady state conditions, they exist in an immature form, with few dendrites and low levels of 
MHC-II molecules. They function as sentinels, constitutively sampling foreign antigen as 
well as endogenous material, (e.g. apoptotic cells) from their environment (10; 15). The 
concept of DCs residing in peripheral tissues in an immature form, capturing antigen, 
migrating, maturing and presenting antigen in regional lymphoid tissues was first described 
for the epidermal Langerhans cells, and was recently referred to as the “Langerhans cell 
paradigm” (16) as summed up in figure 3. 
 3
INTRODUCTION 
 
                                 
 
Figure 1. The Langerhans cell paradigm.  
DCs spend the skin phase in antigen-capture mode, but after encountering pathogen, they migrate to the 
draining lymph node and mature by upregulating costimulatory molecules and MHC class II–antigen 
complexes so they can activate naive T cells.  
 
Reprinted by permission from Nature Publishing Group, Nature Immunology (Heath and Carbone) 2009. 
 
The figure legend has been modified. 
 
APCs are alerted to the presence of potential pathogens through specialized surface 
receptors, called pattern-recognition receptors (PRRs). These receptors may mediate uptake 
of extracellular material (see below) as well as activation signals (2).  PRRs are germ-line 
encoded and highly conserved through evolution, i.e. they are found in similar forms in all 
vertebrates, recognizing molecular patterns common to all microbes (17). Bacteria, viruses, 
fungi and protozoae carry molecules on their surface which have been unchanged for 
millions of years, like lipopolysaccarid, peptidoglycan, flagellin, unmethylated CpG motifs, 
collectively termed pathogen associated molecular patterns (PAMPs) (17). When APCs 
have been activated by PRR-ligand interaction they become very efficient APCs expressing 
costimulatory molecules and cytokines which give additional activation signals to the T cell 
(see below).  
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Toll-like receptors (TLR) are the best studied PRR (18). TLRs are mammal analogues of 
drosophila Toll and vital to the function of the innate immune system (18; 19). 10 different 
TLRs have been described in humans and they differ in their subcellular location, their use 
of adaptor molecules and activation of intracellular signalling cascades. TLRs 1,2, 4, 5 and 
6 are situated on the cell surface and recognize PAMPs of extracellular microbes, such as 
the bacterial cell-wall component lipopolysaccharide (LPS), bacterial flagellin, lipoprotein 
and peptidoglycan (Figure 2). In contrast, TLRs 3, 7, 8 and 9 are located in intracellular 
endosomal-lysosomal compartments, where they recognize RNA and DNA motifs of 
intracellular pathogens such as viruses and intracellular bacteria and parasites (19).  
 
Figure 2. TLR-mediated immune responses.  
TLR2 in concert with TLR1 or TLR6 discriminates between the molecular patterns of triacyl and diacyl 
lipopeptide, respectively. TLR3 recognizes dsRNA. TLR4 recognizes bacterial LPS. TLR7/8 mediates 
recognition of imidazoquinolines and ssRNA. TLR9 recognizes CpG DNA of bacteria and viruses. TLR5 
recognizes bacterial flagellin and TLR11 (only in mice) recognizes uropathogenic bacteria and the protozoan 
parasite Toxoplasma gondii. TLR1/2 and TLR2/6 utilize MyD88 and TIRAP/MAL as essential adapters. 
TLR3 utilizes Trif. TLR4 utilizes four adapters, including MyD88, TIRAP/MAL, Trif and TRAM. TLR7/8, 
TLR9, TLR5 and TLR11 use only MyD88. The MyD88-dependent pathway controls inflammatory responses, 
while Trif mainly mediates type I IFN responses. In addition, TLR7/8 and TLR9 induce type I IFN in a 
MyD88-dependent manner in pDCs  
 
Reprinted with permission from Nature Publishing Group. Cell Death and Differentiation (Kawai) 2006.  
 
The figure legend has been modified. 
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1.2.3. Antigen uptake
Antigens may be endocytosed by a variety of mechanisms (15). Large particulates (bacteria 
or cells) are often recognized by membrane receptors that trigger the formation of large 
endocytic vesicles (phagosomes), a process known as phagocytosis. Macropinocytosis is 
mechanistically similar but in this case the vesicle simply engulfs a large portion of 
extracellular medium (“cellular drinking”). Both these processes require recruiting the actin 
cytoskeleton. Another mechanism to engulf extracellular medium is micropinocytosis, 
which requires the generation of clathrin-coated pits. Finally, receptor-mediated endocytosis 
consists of the internalization of molecules recognized by specific membrane receptors, 
which also trigger the formation of clathrin-coated pinosomes (15). Different classes of cell-
surface receptors are described, the best known of which are Fc-receptors recognizing 
immune complexes, C-type lectins (Langerin, DC-SIGN, Dectin-1, mannose receptor and 
DEC205) recognizing microbial carbohydrates (20), scavenger receptors recognizing  
apoptotic cells and integrins, recognizing apoptotic cells and opsonized antigen. Uptake of 
material by macro- and micropinocytosis is often referred to as “fluid-phase” endocytosis to 
indicate that it is nonspecific rather than being triggered by particular molecular cues  
intrinsic to the endocytosed material.  
 
1.2.4. Antigen processing, presentation and migration of DCs
Once engulfed by the DCs, the material sampled enters the MCH-II pathway, being first 
degraded by proteases in lysosomes. The generated peptides are transported into the 
lysosome-related intracellular compartments which contain MHC-II molecules. The late 
acidic lysosomes fuses with endosomes laden with MHC II molecules derived from the 
endoplasmic reticulum (ER) and the antigen-derived peptides are loaded onto the MCH-II 
molecules. This complex is then transported to the cell surface for presentation to CD4+ T 
cells as immunogenic peptides located in the groove of the MHC-II molecule (15; 21). In 
immature DCs, surface MHC-II molecules have a short half-life and are rapidly 
internalized. Activation of DCs increases the rate of surface MHC II-peptide expression and 
also decreases the turn-over of these complexes, thus facilitating prolonged availability for 
cognate CD4+ T cells.  
Antigens derived from the intracellular compartment, both endogenous constituents 
of the cell and pathogen-derived products, are continuously degraded as part of cell 
homeostasis. Peptides are transported to the ER, where they are loaded on to MHC I 
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molecules and subsequently transported to the cell surface for presentation to CD8+ CTLs 
(15). Some DCs also have the ability for so called cross-presentation, i.e. antigen sampled 
from the extracellular environment can enter the endogenous pathway and be presented on 
MHC class I molecules, thus generating a CTL-response against antigens not necessarily 
expressed in DCs (15; 22). Because viruses and some bacteria and parasites are obligatory 
intracellular pathogens, this pathway is important to alert the adaptive immune system to the 
presence of such an infection. This pathway is also important in immune responses to cancer 
(23).  
 Different pathogens express different PAMPs, and the combination of these PAMPs 
serves as a fingerprint that triggers a specific set of PRRs on DCs, leading to the integration 
of signaling pathways to tailor the immune response to that specific pathogen (20; 24). 
TLR-engagement indicates danger and activates down-stream cell signalling cascades, most 
of them involving the adaptor molecule MyD88 (Figure 2). This results in expression of 
pro-inflammatory cytokines enhancing further down-stream effects on the adaptive immune 
response. TLR-signaling initiates a maturation process in the DC, characterized by 
upregulation of molecules for antigen presentation, i.e. MHC-I and II, and co-stimulation of 
T cells, such as CD80/86 (also called B7.1 and B7.2) (Figure 3) and CD40. Simultaneously, 
antigen uptake by phagocytosis and macropinocytosis as well as receptor mediated 
pinocytosis is downregulated but all endocytic activity is not shut down and mature DCs 
retain some antigen sampling activity (15). Endogenously produced molecules released at 
sites of ongoing inflammation, socalled damage associated molecular patterns (DAMPs), 
may also activate DCs through TLRs or other surface receptors (25; 26). DCs express 
several DAMP-receptors, such as protease-activated receptors (PARs) (27), C5a and C3a 
anaphylatoxin receptors (28), prostaglandin receptors (29) and purinergic receptors sensing 
extracellular ATP (30). DCs can also be activated by various pro-inflammatory cytokines 
produced by other cells, such as IL-1 and TNF-, although in order to become fully capable 
of initiating an adaptive immune response, direct TLR-signalling is necessary (25; 31). 
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Figure 3. The receptors involved in the interplay of the innate and adaptive immune systems. 
Recognition of the pathogen-associated molecular pattern (PAMP) by pattern-recognition receptors, such as 
the toll-like receptors, generates signals that activate the adaptive immune system. Endocytic pattern-
recognition receptors bind to components of microbial cell walls and mediate the uptake and phagocytosis of 
pathogens by antigen-presenting cells (macrophages and DCs). Proteins derived from the microorganisms are 
processed in the lysosomes to generate antigenic peptides, which form a complex with major-
histocompatibility-complex (MHC) class II molecules on the surface of the APC. These peptides are 
recognized by T-cell receptors. In the case of the signaling class of pattern-recognition receptors, the 
recognition of pathogen-associated molecular patterns by toll-like receptors leads to the activation of signaling 
pathways that induce the expression of cytokines, chemokines, and costimulatory molecules. Therefore, 
pattern-recognition receptors have a role in the generation of both the peptide–MHC-molecule complex and 
the costimulation required for the activation of T cells. 
 
Reprinted by permission from Massachusetts Medical Society, The New England Journal of Medicine 
(Medzhitov and Janeway) 2000. The figure legend has been modified. 
 
 Upon activation and maturation, surface expression of chemokine receptors on DCs 
is altered. Chemokines are small chemical substances that function as leukocyte 
chemoattractants. Produced locally, they direct the migration of target cells against a 
concentration gradient (32; 33). Activated DCs upregulate the chemokine receptor CCR7, 
which recognizes the stroma-derived chemokine CCL21, expressed in lymphoid tissues. 
This receptor-ligand interaction facilitates the migration of tissue-resident DCs from 
peripheral tissues to the T-cell areas of draining lymph nodes (34). 
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1.2.5. Activation of CD4+ T cells 
Naïve T cells traffic the T-cell regions of secondary lymphoid organs, such as the spleen 
and peripheral lymph nodes. After arrival in the lymph node, DCs move about within T cell 
areas, making transient contact with a large number of naïve T cells and more sustained 
contact with those that recognize antigens presented on the DC surface (35).  
Interactions between surface molecules on DCs and cognate T cells create an 
interface at which signalling between the two cells takes place, termed the immunological 
synapse. Three types of signals from the DC are required for full activation and polarization 
of T cell responses (Figure 4). 
                
Figure 4. Signal 1, 2 and 3.  
Within the immune synapse formed between APCs and T cells, three signals are required for antigen-specific 
T cell activation. Signal 1 comprises the presentation of antigen peptide, in the context of MHC class II 
molecules, which is recognized by the antigen-specific TCR. Signal 2 involves the stabilization of the synapse 
through adhesion molecules and the generation of signals via costimulatory molecules present on the surface 
of APCs and T cells. CD80/CD86 on APCs interact with their receptor, CD28, on T cells to generate 
activatory signals, while interaction with cytotoxic T lymphocyte–associated protein 4 (CTLA4) generates 
inhibitory signals (not shown). Signal 3 is produced by the secretion of cytokines by APCs, which signal via 
cytokine receptors on T cells in order to polarize them toward an effector phenotype. Ag, antigen. 
 
 
Reprinted by permission from American Society for Clinical Investigation, Journal of Clinical Investigation 
(Gutcher and Becher), 2007  
The antigen derived peptide presented in the groove of the MHC II-molecule is recognized 
by the TCR and provides signal 1 to the naïve CD4+ T cells, conferring information about 
antigen specificity. Costimulatory molecules on DCs upregulated as part of the maturation 
process, the best studied of which are CD80 and CD86, interact with CD28 on T cells and 
provide signal 2, required for full activation of naïve T cells. Signal 3 is given by the 
cytokines produced by the DC and induces polarization of naïve CD4 T cells into various 
subsets of effectors (36). The efficiency of T-cell activation depends on the density of DCs 
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and amount of antigen-MHC-complexes (37) as well as the level of costimulation. All 
signals appear to be required for full effector T-cell generation (36). Some costimulatory 
molecules have recently been shown to confer polarization signals, like OX40 for TH2 
polarization (38) and ICOS for Treg induction (39). 
DCs translate information about the invading pathogen into a cytokine-gene 
expression-profile that directs the appropriate T cell differentiation pathway (36) (Figure 5).  
           
Figure 5. Induction of T cell subsets.  
Prompted by different types of interleukin (IL) produced by DCs and other sources, undifferentiated T helper 
cells can develop into the T 1 or T 2 lineages. In an inflammatory response, TGF-H H 1 and IL-6 promote the 
development of another lineage, T 17 cells that produce IL-17. In contrast, interferon-  (IFN-H ) and IL-4, 
products of T 1 and T 2 cells, inhibit T 17 differentiation. TGF-H H H 1 boosts expression of the IL-23 receptor, 
promoting expansion of T 17 cells by IL-23. But TGF-H 1 also promotes the development of another lineage 
— regulatory T (Treg) cells — by inducing the transcription factor Foxp3, an outcome that is inhibited in the 
presence of IL-6. Development of T 1 and TH H2 cells depends on specific STAT proteins and other gene-
transcription factors such as T-bet and GATA-3. STAT-3 is probably involved in TH17 differentiation, and 
RORt (not shown) has recently emerged as another T 17-lineage-specific factor. H
 
Reprinted by permission from Nature Publishing Group, Nature (Tato and O’Shea) 2006. 
The figure legend has been modified. 
 
In the presence of intracellular microbes, such as viruses, intracellular bacteria and 
parasites, DCs produce IL-12 and type 1 IFNs (10). This results in induction of TH1 cells 
characterized by the production of IFN-. Activated TH1 cells help to activate macrophages 
and CD8+ CTLs. Unregulated activation of these responses may result in immunopathology 
and autoimmune disorders.  
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Whereas the link between DCs and TH1 responses is well defined, the mechanisms 
that induce TH2 responses have been less clear, as DCs do not produce IL-4, the main TH2-
inducing cytokine (40). TH2 cells produce IL-4, IL-5, IL-9 and IL-13, stimulating IgE 
production, as well as eosinophil- and mast cell-differentiation. These factors are important 
in combating extracellular microbes but are also involved in allergies (41). Recently it was 
shown that initiation of TH2 responses was dependent on basophils. These cells were able to 
present antigens to naive T cells concomitant with IL-4 production, initiating TH2 responses 
towards antigens with protease activity (42). Thymic stromal lymphopoietin (TSLP) has 
also been shown to play an important role in conditioning DCs to induce TH2-responses 
(43).  
TH17 cells are characterized by the production of IL-17, IL-22 and IL-6 (44). TH17 
differentiation depends on the presence of IL-6, IL-23 and low levels of TGF- in mice (44), 
whereas in humans TH17 cells are induced by IL-21 and TGF- (45) and possibly some 
other combinations of cytokines (46). This cell subset stimulates phagocytes to clear 
extracellular microbes, but have also been implicated in the pathogenesis of several 
autoimmune diseases (47; 48). Recently a fourth effector TH subset has been defined: 
Follicular Helper T cells (TFH), a subset dedicated to supporting B-cell maturation within 
lymphoid follicles (49).  
All these qualitative different responses are highly efficient when activated under 
specific inflammatory conditions but are in need of tight control in order to minimize 
collateral damage. During steady state conditions, i.e. no danger signals present, DCs and 
macrophages constitutively phagocytose apoptotic cells and present innocuous and self 
antigens to T cells in an immature form (50). Antigen presentation to naïve T cells with low 
levels of costimulatory molecules and high levels of the immunosuppressive cytokines 
TGF- and IL-10 results in the induction of regulatory T cells (Tregs) with suppressive 
capacity (see below). These cells are critical in order to maintain immunological 
homeostasis and minimize collateral damage to host tissues under inflammatory situation 
(51; 52). 
At the molecular level, the differentiation of naïve T cells into specific effector 
subsets is dependent upon the induction of lineage-specific transcription factors: Tbet for 
TH1 cells, GATA-3 for TH2 cells, RORt for T 17 cells and FOXP3 for T (Figure 5). TH regs FH 
cells are dependent on Bcl6 induced by IL-6 and IL-21 (53). 
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Subsequent to activation of T cells, DCs may in turn receive stimulation signals by 
effector T cells, primarily through interactions between CD40L on activated T cells and 
CD40 on DCs, thus creating a positive feed-back loop (54). 
 
1.2.6. Imprinting addressins on T cells 
In addition to inducing and tailoring adaptive immune responses to best combat the 
offending microbe, DCs also help activated T cells orientate in the body. Adhesion 
molecules are induced on the activated T cells, socalled “addressins” or “homing 
molecules”, which specifically interact with corresponding molecules upregulated on the 
blood vessels of the organ in which the DC originated. This mechanism ensures that when T 
cells enter the blood stream after activation, they will “home” to the tissues where the 
pathogen first made entry (55; 56). Naïve T cells express the adhesion molecule CD62L and 
CCR7, which restricts their migration to secondary lymphoid tissues (55). In contrast, 
activated T cells downregulate lymphoid-tissue-homing receptors and upregulate tissue-
specific adhesion molecules and chemokine receptors that target their migration to non-
lymphoid tissues. This imprinting of tissue-homing properties is best described for the gut 
and skin. Thus, T cells primed by DCs in Peyer’s patches and mesenteric lymph nodes 
express addressins 47 and CCR9, which interact with the adhesion molecule MadCAM-1 
and CCL25, which enable them to access the gut mucosa upon reentering the blood stream 
(57). In contrast, T cells that are primed in peripheral lymph nodes upregulate cutaneous 
leukocyte antigen (CLA), CCR4 (58) and CCR10 (59). These processes have been shown to 
be at least partly dependent on local vitamin metabolism. In the gut local vitamin A 
metabolized by DCs induced gut homing properties in T cells (60), whereas in the skin 
sunlight induced vitamin D metabolized by DCs induced skin homing of T cells (59).
Distinct homing phenotypes for leukocyte trafficking to the respiratory tract have yet to be 
defined, but recent information suggest the involvement of  4 1-integrin and lymphocyte 
function-associated antigen 1 (LFA1), which correspond with their counterparts VCAM1 
and intercellular adhesion molecule 1 (ICAM1), respectively, constitutively expressed on 
the vessel wall in the bronchial mucosa (61).   
Locally produced mediators, such as chemokines, at the site of an infection or 
allergen encounter, will increase endothelial expression of selectins to initate leukocyte 
rolling, followed by the expression of integrins to arrest the leukocyte and assist its passage 
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into the perivascular space. Extravasated leukocytes will then travel up the chemokine 
gradient to the site of infection or allergen exposure (55). 
 
1.2.7. DC subsets 
DCs are a heterogenous population of bone-marrow derived, highly motile and flexible with 
respect to both structure and function, changing their modus operandi within a short time 
span. Their precise characterization is made difficult by their dynamic phenotype, with 
changes in surface markers used for identification as well as function, depending on the 
situation in which they are examined. DCs may be divided into migratory and lymphoid 
tissue resident DCs (62) or by their presumed origin (myeloid versus plasmacytoid DCs). 
This latter classification is the most widely used in humans and this also encompasses 
functional differences (63).  
In peripheral blood, myeloid DCs (mDCs) and plasmacytoid DCs (pDCs) have been 
defined based on the expression of the integrin CD11c (64). mDCs represent the largest DC 
subset both in blood and peripheral tissues. They are commonly defined as HLA-DR+ 
CD11c+ DCs and they carry additional socalled myeloid markers, such as CD33, CD13 and 
CD11b (64). mDCs are potent inducers of T-cell activation. LCs, a subset of mDCs, are 
located primarily in the epidermis. They contain Birbeck granules and express CD1a and 
Langerin/CD207 (65). LCs were among the first DCs described and early studies suggested 
that they are central in T-cell mediated immunity, such as in contact hypersensitivity (CHS) 
and herpes simplex infections (66-68). However, the concept of LCs as primarily acting as 
initiators of immune responses has been questioned recently, as T cell activation can be 
induced in the absence of these cells (69). In mice, LCs were found to be unable to induce 
CD8 responses against HSV infection (70). Indeed, studies have indicated that CHS is 
actually dampened by the presence of LC, thus implicating these cells in tolerance induction 
(71).  
-pDCs are CD11c  and have a plasmacytoid appearance (12). They are characterized 
by the coexpression of CD45RA and CD123 (-chain of the IL-3 receptor) (72). pDCs are 
primarily found in lymphoid organs and are rare in peripheral organs except for the liver 
(73). They are characterized by their ability to produce large amounts of type 1 interferon 
(IFN) (the best studied of which is IFN- ) during viral infection (12; 63). In addition to 
inducing a state of resistance to viral infection in tissue cells, type 1 IFNs also activates 
various immune cells, thus initiating and orchestrating innate and adaptive antiviral 
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immunity (63; 74). pDCs are clearly less effective than mDCs in inducing T cell responses 
(75) and are by some considered to be precursor DCs as they acquire typical DC features 
only after contact with inflammatory stimuli (72). Production of IFN has also been shown to 
be central to the role of pDCs in various autoimmune processes (74), including lupus 
erythematosus (76) and psoriasis (77). However, they have also been implicated in tolerance 
induction both in mice (78; 79) and human models (80; 81) 
pDCs were initially believed to have lymphoid origin, based on the lack of myeloid 
markers (72) and the expression of some lymphocyte features. However, recently several 
studies have demonstrated that early common precursors can give rise to mDCs, pDCs as 
well as monocytes/macrophages in mice (82-84) and humans (85). mDCs and pDCs show 
differential expression of TLRs. Whereas mDC have been shown to express all TLRs except 
TLR7 and 9, hence primarily sensing extracellular microbes, pDC express the intracellular 
TLR7 and 9, associated with virus recognition (12; 86).  
 
1.2.8. Trafficking of DCs 
DCs and macrophages are derived from precursors in the bone marrow. Distinct 
subpopulations of circulating monocytes are thought to give rise to resident tissue DCs and 
macrophages (73). mDCs accumulate at particularly high numbers near the epithelial 
surfaces, such as skin and mucosae. In contrast, pDCs enter T cells areas of secondary 
lympoid tissues through high endothelial venules (HEVs), thus acting more like naïve 
lymphocytes (73).  
In the steady state, the turn-over of tissue DCs varies from days in the airways (87) 
to weeks for the epidermal LCs (65; 88). Inflammatory stimuli increase this turn-over 
dramatically (89; 90). Cytokines produced locally at the site of inflammation are carried 
with the blood stream and stimulate the bone marrow to producing and releasing more DC 
precursors. The most important cytokines stimulating DC development are fms-like tyrosine 
kinase 3 ligand (Flt3L), granulocyte-macrophage colony stimulating-factor (GM-CSF), 
CSF-1 and TGF- (88). Under inflammatory conditions monocytes are recruited at a higher 
rate, due to increased expression of chemoattractants and adhesion molecules on endothelial 
cells (91). Recruited monocytes then differentiate into DCs and several cytokines, including 
GM-CSF, TNF- , and IL-4, may play a role in this process (88). Animal studies have shown 
that DC precursors are recruited to airways through mechanisms dependent on the 
chemokine receptors CCR1, CCR5 and possibly CX3CR1 both under steady-state 
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conditions and in response to inflammatory stimuli, whereas CCR2 and CCR6 may be 
important for DC recruitment during secondary immune responses in allergy models (92).  
pDCs do not migrate from peripheral tissues to lymph nodes, following the 
Langerhans cells paradigm, but may acquire antigen locally and enter lymphatic tissue via 
the blood stream (73). pDCs are continuously replaced by blood-borne precursors but the 
exact mechanisms that control pDC trafficking remain to be identified  (88).  
In contrast to most DCs, LCs are radioresistant and repopulate locally in the steady 
state, either through self-renewal or through a local hematopoietic precursor that takes 
residence in the skin throughout life under steady state conditions (93). During 
inflammation, LCs are repopulated by blood precursors, most likely monocytes (94). Also 
for dermal DCs, evidence of local self-renewal has been found (95). For the skin, the 
chemokines MCP and CCL20 interacting with CCR2 and CCR6 respectively (96; 97), have 
been shown to be important for the recruitment of DCs. This chemokine is highly 
upregulated in inflamed skin such as in psoriasis, resulting in upregulation of endothelial 
adhesion molecules, with which circulating DC-precursors interact. 
In addition to DCs located in peripheral tissues, which show the classic migratory 
pattern, termed the Langerhans cell paradigm, there are also resident, non-migratory DCs in 
the spleen and lymph nodes, although studies on these populations are primarily performed 
in mice and little is known about their human counterparts (62; 73). 
 
1.3. Macrophages
Macrophages are phagocytic cells of the innate immune system with antigen presenting 
capacity, present in virtually all tissues. Whereas peripheral tissue DCs are characterized by 
a migratory behaviour, homing efficiently to T cells zones of lymphoid organs for optimal 
interactions with T lymphocytes, macrophages are more sessile, exerting their physiologic 
role on site in peripheral tissues (98). They develop from circulating precursors, believed to 
be monocytes, which migrate into different tissues during steady-state or in response to 
inflammation, developing into a variety of long-lived tissue-specific macrophages, like 
Kuppfer cells in the liver, microglia of the brain and osteoclasts of the bone (98; 99). The 
role of macrophages in phagocytosis of pathogens is best described. They share many of the 
cell surface molecules, including some TLRs and are basically capable of the same 
mechanisms for endocotyosis and phagocytosis as DCs. Upon ingestion of microbes, they 
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degrade the particles through the generation of inducible nitric oxide synthase (iNOS) and 
highly reactive oxygen species (ROS) generated through ”the respiratory burst” and produce 
proinflammatory cytokines (100; 101). Processed antigen may be presented to cognate T 
cells. Macrophages may express costimulatory molecules but are not generally believed to 
be able to activate naïve T cells. They may activate effector memory T cells on site in 
peripheral tissues, which have a lower threshold for activation than naïve cells (5). 
Macrophages primarily activate TH1-cells, through production of IL-12. In turn, 
macrophages may receive activation signals from activated TH1 cells, through IFN- 
production and CD40L-CD40 interactions. This results in increased efficiency in microbial 
degradation, particularly important in killing intracellular pathogens like mycobacteria 
(102).  
Macrophages are also central in tissue homeostasis, wound healing, recycling iron, 
clearing senescent erythrocytes and cellular debris during tissue remodeling. They may 
produce immunosuppressive cytokines and modulate adaptive immune responses, also 
contributing to resolution of inflammation (103). Recently a new classification of 
macrophages has been suggested, taking this variety of functional phenotypes into 
consideration: i) classically activated macrophages, producing proinflammatory cytokines 
like IL-12 and TNF- in response to pathogens and IFN-, ii) regulatory macrophages, 
producing the immunosuppressive cytokine IL-10 in response to apoptotic cells and Tregs 
and iii) wound healing macrophages, exerting homeostatic effects in response to IL-4, 
produced during tissue damage (98). Importantly, macrophages adapt to their cytokine 
environment and may change their physiology in response to endogenous stimuli from 
innate or adaptive immune signals (98). Human macrophages are generally identified by the 
surface marker CD163, which is an endocytic receptor for hemoglobin-haptoglobin 
complexes and the intracytoplasmic CD68. However, no specific markers exist as yet, 
which may identify the different functional phenotypes.  
DCs and macrophages are clearly related and it has recently been argued that the 
distinction of the two populations as separate entities may be artificial (104).  
 
1.4. Regulatory T cells (Tregs)
In 1995, the concept of a specialized subset of T cells exerting dominant suppressive 
activities was reborn and eventually generally accepted (105; 106). A number of different 
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regulatory T cell (Treg)  populations have since been described (TR1, TH3 and CD4+ +CD25  T 
cells) and shown to exert modulating effects on the immune system by a variety of 
mechanisms (107; 108). CD4+ +CD25  Tregs commonly express the transcription factor 
forkhead box protein 3 (FOXP3), which is thought to be crucial for both their differentiation 
and maintenance of suppressive function (109; 110). The important regulatory role of 
FOXP3+ Tregs has clearly been established through identification of the human X-linked 
inherited disease designated IPEX (immune dysregulation, polyenocrinopathy, enteropathy, 
X-linked) syndrome - an early onset lymphoproliferative disease that affects several organ 
systems (111). Many patients with IPEX syndrome suffer from severe atopic diseases and 
scurfy mice (mouse homolog of IPEX) also show allergic dysregulation (112). Reactive 
airways disease has also been noted in children with a defect in FOXP3 giving a less severe 
form of disease than the IPEX syndrome (113).  
+FOXP3  Tregs are broadly divided into naturally occurring Treg (nTreg) and 
adaptive/inducible Treg (iTreg) populations (114). The thymus derived FOXP3+ naturally 
occurring T  (nTreg reg) are thought to be important for the control of autoreactive T cells and 
thus prevention of autoimmune diseases (115; 116) but they may also contribute to 
mediating tolerance towards foreign antigen (117). More recently it has become clear that 
FOXP3+ Tregs can develop outside the thymus under certain tolerogenic conditions (117-
120) and these represent the adaptive/inducible T (iT ). iTreg reg regs are thought to develop from 
naïve cells in the periphery (114) and also from effector T cell populations (107; 121), 
exemplifying the plasticity of the T cell response. Peripheral induction of Tregs may represent 
an important mechanism to generate tolerance to exogenous antigens, such as commensal 
bacteria, food and pollen antigens. Especially at mucosal surfaces, where the immune 
system encounters innocuous antigen, often in the presence of microbes, the induction of 
specific tolerance is vital to homeostasis (122; 123). Requirements for the peripheral 
induction of Tregs include suboptimal TCR signalling or a combination of strong TCR 
signalling and high levels of TGF- (119; 124; 125). A role for both TGF- and retinoic 
acid has been found in the generation of peripherally induced Tregs in the gut (120; 126). 
This retinoic acid is produced by a specific subset of CD103+ DCs in the lamina propria, 
thus acting as tolerogenic DCs (126; 127).  
Tregs can suppress the function of effector T cells, B cells, DCs, macrophages, mast 
cells, NK cells and NKT cells through a variety of different mechanisms (107). Naturally 
occurring CD4+ +CD25  T cells seem to mediate their suppressive properties primarily 
through direct cell-cell contact (128; 129), although production of cytokines, in particular 
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IL-10, TGF- and recently IL-35 (130) has also been shown to contribute. In addition to 
direct effects on effector cells, Tregs also exert immunosuppressive effects via interactions 
with DCs, inducing them to become tolerogenic. Expression of the membrane bound 
inhibitory molecule CTLA-4, T  has been shown to be vital to Tregs reg function (131) and 
exerts its effects probably primarily through interactions with CD80/CD86 on DCs (107; 
132). In mice, T  have also been shown to control the number of DCs (133). regs
 
1.5. APCs and Tregs in disease
1.5.1. APCs in the airways 
Like other epithelial surfaces, the airway mucosa is lined with a dense network of APCs, 
consisting of DCs and macrophages (61). Airway mucosa DCs (AMDCs) are strategically 
located both within and beneath the surface epithelium, which allows their sentinel function 
(61). The airway mucosa is constantly exposed to large amounts of foreign antigen, both 
pathogens and innocuous material like pollen and house dust mite (HDM), common 
aeroallergens that trigger immune pathology in allergic individuals (61). The regional 
immune system thus faces a considerable challenge in determining against which antigens 
an immune response should be initiated. Animal studies have demonstrated a high turn-over 
rate of AMDCs compared with skin (87). In upper airways of humans, a large fraction of 
APCs coexpress DC and macrophage markers, as opposed to findings in the skin (134; 135), 
suggesting that they are newly recruited from the circulation. In previous studies only very 
few APCs have been detected in fetal and infant bronchi (136). pDCs are found at low 
densities in the lungs of adults (137) but few studies exist and until now, no studies 
characterizing these cells in the airways of children have been performed. In mice, a subset 
of CD103+ DCs  express tight junction proteins, like zona occludens-1 and claudin (138) 
enabling them to penetrate the epithelium and form dendritic extensions into the lumen, 
where antigen may be sampled (see below), but whether intraepithelial AMDCs in humans 
express CD103 has not been confirmed.  
There is evidence that antigens entering via the respiratory route generally induce 
tolerance or a low-level TH2 immune response as the default pathway even in the presence 
of TLR-signalling (61; 139), making the airways a vulnerable site for development of 
allergy. However, it is assumed that stronger TLR-stimulation by microbial products may 
skew the ensuing response in a TH1-direction (140-142). The continuous DC-mediated 
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transport of inhaled Ag to the bronchial lymph nodes was shown to be critical for the 
induction of tolerance to innocuous Ags (143). 
The interplay between epithelial cells and DCs, in which epithelial cells prime or 
“educate” tissue-resident DCs is being increasingly appreciated (25; 144; 145). TGF- is a 
molecule with immunomodulatory effects and is produced by epithelial cells and Tregs (146). 
Mice lacking the transcription factor Runx3, involved in downstream TGF--signalling, 
spontaneously develop asthmatic features. This involves increased numbers of lung DCs 
with a mature phenotype, expressing high levels of MHC-II, OX40L and CCR7 (147). 
 
1.5.2. APCs in asthma  
Asthma is a common chronic inflammatory disease of the airways, characterized by airway 
hyperresponsiveness (AHR) and acute exacerbations driven by TH2 cells (148). Atopic 
individuals have a genetic predisposition to TH2-dominated immune responses and 
increased risk of developing allergic asthma, hayfever, food allergy and atopic eczema 
(149). As yet unknown environmental factors have resulted in a dramatic increase in the 
prevalence of asthma, and the associated allergic diseases primarily in the westernized 
world in the past few decades (150). Specific IgE- production results in sensitization to 
common allergens, which drives the pathologic process of allergic asthma (148; 151). The 
TH2-associated cytokines IL-4 and IL-13 stimulate IgE-production, IL-5 recruits eosinophils 
and IL-9 enhances mast cell growth, thus shaping the atopic immune response (148). As 
upstream inducers of T-cell activation, DCs are essential in priming these TH2-responses 
and thus vital to the pathogenesis of this common disease (152). 
Presentation of inhaled antigen to naïve TH cells occurs primarily in the bronchial 
and lung draining lymph nodes (141; 153; 154) and DC-T-cell interactions at these sites 
determine the outcome of the resulting immune response. DC-mediated activation of 
memory T cells has been shown to take place locally in the mucosa (155; 156). Mouse 
studies have shown that sensitization to airway allergen involved activation of DCs prior to 
the onset of T +H2-mediated inflammation (157) and that depletion of CD11c  DCs during 
allergen challenge inhibited the development of pathologic characteristics of asthma (158). 
Epithelial cells in asthmatics have been shown to produce TSLP, a key cytokine in 
triggering myeloid DCs to become TH2-inducing (43) (Figure 6). TSLP-activated DCs 
stimulate naïve T cells to differentiate into proinflammatory TH2 cells that produce IL-4, IL-
5, IL-13 and TNF- but not IL-10, a T-cell phenotype found in asthmatic airways (38; 159). 
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This polarizing capacity has been shown to involve the induction of the costimulatory 
molecule OX40L on DCs. Moreover, TSLP-activated DCs produce the TH2-attracting 
chemokines CCL17 and CCL22 which increase recruitment of TH2 cells to the site of 
inflammation (38). The polarization of TH2 cells induced by TSLP-activated DCs is further 
enhanced by IL-25, produced by epithelial cells, basophils and eosinphils in response to 
 
Figure 6. Interactions between 
Epithelial Cells and Dendritic Cells 
in the pathogenesis of asthma 
Dendritic cells (DCs) sample the airway 
lumen by forming dendritic extensions in 
between epithelial cells. The cells form 
tight junctions with epithelial cells by 
expressing occludin and claudin family 
members as well as zona occludens-1 
(ZO-1). In addition, the cells attach to 
airway epithelial cells via E-cadherin and 
CD103 expressed by a subset of DCs that 
probes the airway lumen. Enzymatically 
active allergens can activate protease-
activated receptors (PARs) expressed by 
epithelial cells followed by nuclear 
factor-B (NF-B) activation and the 
production of chemokines and cytokines 
by epithelial cells that attract and activate 
DCs. Allergens often contain Toll-like 
receptor (TLR) agonists and C type lectin 
agonists and triggering through these also 
induces NF-B activation and DC 
Reprinted by permission from Elsevier, Immunity (Lambrecht and 
Hammad) 2009  
activation either directly or indirectly via 
effects on epithelial cells that also express 
TLRs and C-type lectin receptors. 
 
allergens (160; 161) and IL-33 (162). Several aeroallergens have been shown to promote 
TH2-inducing mDCs, partly through interactions with the epithelium (152; 161). For 
example, Bet v from birch pollen and Der p 1 and Der p 9 from HDM have intrinsic 
protease activity (144). This activity has been shown to contribute to impaired TH1 and 
enhanced TH2 immune responses by several mechanisms (144) (Figure 6).  
In several mouse models pDCs have been shown to have immunomodulating effects, 
protecting against asthmatic inflammation (79; 163). Also, in children an inverse 
relationship between circulating pDCs numbers and the risk of childhood wheezing has 
been found (164). 
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1.5.3. T  in asthma regs
An increasing body of evidence suggests that Tregs are important in modulating the 
inflammatory process in human asthma (61; 165-167). Children suffering from IPEX, have 
severe allergic manifestations in addition to widespread autoimmune disorders (111). Tregs 
were found to be impaired in the cord blood of neonates at hereditary risk of allergy (168). 
Successful allergy immunotherapy is associated with increased number of Tregs and elevated 
levels of IL-10 and TGF- (169). In several mouse models of asthma, Tregs have been shown 
to be central in ameliorating symptoms. Repeated exposure of mice to low-dose allergen 
promoted the development of Tregs, which could prevent allergic sensitization in naïve mice 
upon adoptive transfer (170). Induction of Tregs has been shown to reverse AHR (171; 172) 
and adoptive transfer of Tregs could suppress allergic inflammation in an IL-10 dependent 
manner (173). Moreover, Tregs were also shown to be able to suppress established 
inflammation and prevent airway remodelling (174). 
 
1.5.4. APCs in the skin 
LCs are the primary APC in the epidermis. As described above, the concept of LCs as 
primarily initiators of immune responses has been questioned recently. Several studies 
suggest a role for LCs in the transport and presentation of endogenous skin antigens to the 
skin-draining lymph nodes under steady-state conditions and thus a role in tolerance 
induction (175-177).  
In the dermis various DC populations have been described, collectively termed 
dermal dendritic cells (DDCs) (97). In the steady state, the main population of DDCs 
expresses CD11c and CD1c similar to mDCs in blood. This subset has been termed 
“resident DCs” as opposed to other DC populations which accumulate under various 
inflammatory conditions (97). Some DDCs also express the LC marker Langerin and recent 
studies in mice have shown that these cells are distinct from LCs in the epidermis (65). Only 
very few pDCs occur in skin under homeostatic conditions (97). 
Skin APCs also include distinct populations of macrophages (135; 178). They are 
characterized by the expression of CD163 and in normal dermis, there is little overlapping 
expression of this marker and the DC marker CD11c (135).  
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1.5.5. APCs in psoriasis 
Psoriasis is a chronic inflammatory disorder of the skin, which affects 1-3 % of Caucasians. 
It is associated with severe impairment of quality of life (179) and increased mortality (180). 
A combination of environmental and genetic factors confers susceptibility to the disease and 
a dysregulated immune response is central to the pathologic process in the skin (181). 
Pathological findings are characterized by hyperproliferating keratinocytes, resulting in a 
severely thickended epidermis (acanthosis) with elongated rete ridges, hyperkeratosis and 
focal parakeratosis. Cellular infiltrates are found in both epidermal and dermal 
compartments (181). The disease is widely held to be autoimmune but the autoantigen 
triggering the inflammatory cascade remains unknown (182). Psoriasis is associated with 
other autoimmune diseases such as Crohn’s disease and rheumatic disorders. Understanding 
of immune pathology in psoriasis has relevance to other chronic inflammatory conditions, 
because of shared genetic variants, common immunological pathways and therapeutic 
targets (183). Unspecific events like local trauma and infections with group A Streptococci 
may trigger exacerbations (Figure 7). 
IFN- 
TNF- 
IL-17 
IL-22 
 
Figure 7. An emerging model of psoriasis pathogenesis in humans.  
Many insults can lead to the activation of dermal dendritic cells, a key initiating step in the development of 
psoriasis in predisposed individuals. Activated dendritic cells induce the proliferation of autoreactive T cells 
within the dermis, inducing production of IFN-, TNF-, IL-17 and IL-22 which in turn induces the production 
of MCP-1 and other chemotactic cytokines by epidermal cells. These chemotactic agents induce influx of 
monocytes from the blood, which undergo differentiation into macrophages and myeloid dendritic cells. Dermal 
macrophages may, once activated by T-cell or DC-derived cytokines, then produce large amounts of TNF-, 
leading to the skin changes observed in psoriasis.  
 
Reprinted by permission from American Society for Clinical Investigation, Journal of Clinical Investigation 
(Clark and Kupper) 2006.  The figure and legend have been modified. 
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Immune cell accumulating in psoriatic plaques consist of activated memory 
populations of skin-homing (CLA+) CD4+ + and CD8  effector T cells, DCs as well as 
neutrophils and macrophages (183). Lesional lymphocytes produce TH1-cytokines, 
primarily IFN- and TNF-, and the use of anti-TNF-agents is now a well established 
treatment modality for this disease (184). However, more recently a prominent role for TH17 
cells has been demonstrated (48; 182; 185). Whereas TH1 and TH17 cells constitute the 
proximal cause of immune pathology, through their production of inflammatory cytokines, 
DCs and possibly macrophages as upstream activators of T cells are the cells believed to 
initiate this pathologic process. Both mDCs and pDCs are increased in psoriatic lesions (77; 
186). In particular, a population of "inflammatory" myeloid DCs expressing CD11c but 
negative for CD1c is dramatically increased in psoriasis lesions (97; 186). A specialized 
inflammatory TNF- and iNOS producing, so-called “Tip-DC” has been described (187; 
188). These cells were found to induce proliferation of T cells as well as stimulate the 
production of TH1 and TH17 cytokines (186). It is likely that these Tip-DCs are contained 
within the CD11c+ -CD1c  mDC population (97). The fact that they produce proinflammatory 
cytokines supports a role for these DCs as effector cells as well as inducers of T cells (97). 
Pathogenicity of Tip-DCs in psoriasis is underscored by the rapid downmodulation of their 
products TNF- , iNOS, IL-20 and IL-23 during treatment with effective therapies (187; 
189). Recently a new therapeutic monoclonal antibody directed against p40, the common 
subunit of IL-12 and IL-23 has been shown to be effective, underscoring the role for these 
DC-derived cytokines in driving psoriasis (190).  
Although pDCs are a minority of all DCs in psoriasis, they have been shown to be 
important in driving immune pathology through their production of IFN- (77; 191). 
Recently a triggering mechanism was described in which the antimicrobial peptide LL37, 
which is upregulated in psoriasis, generates a complex with endogenous DNA, activating 
pDCs through TLR9, thus inducing IFN- production (192). It was also shown that the same 
is true for endogenous RNA and these complexes could also activate mDCs via TLR8 and 
TLR7 (193).  
In psoriatic lesional skin, the density of epidermal LCs was found to be lower than in 
normal skin (194). Also, one study in psoriatic patients found that LCs in non-lesional skin 
was showed impaired migration upon stimulation with factors that induced migration of 
LCs in healthy controls (195).  
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Macrophages also accumulate in psoriatic lesions and have been shown to be a 
source of pathogenic TNF- in mouse models of psoriasis (196; 197). There is also evidence 
that macrophages contribute to psoriasis pathogenesis in humans (198; 199). 
 
1.5.6. T  in psoriasis regs
In several autoimmune disorders Tregs have been shown to be impaired in their function 
(200; 201). The inflammatory environment in psoriatic skin favours recruitment and 
development of pathogenic T cells (182). However, studies have shown that Tregs 
accumulate in lesional dermis along with putative pathogenic effector T cells (202; 203).   
80 % of circulating CD4+ high +CD25 FOXP3  Tregs were found to express the skin homing 
molecule CLA (204), indicating that Tregs are important in maintaining immune homeostasis 
in the skin. However, a functional study on patients with psoriasis found Treg-populations in 
peripheral blood as well as in lesional skin to be impaired in their immunoregulatory 
capacity, suggesting that a malfunction in these cells may contribute to the disorder (205). 
The proinflammatory cytokine IL-6 renders effector T cells refractive to suppression by 
Tregs (206) and recently it was shown that IL-6 signalling in psoriasis prevented immune 
suppression by T + + (207). One study also found that CD4 CD25  Tregs regs differentiated in 
vitro from CD34+ hematopoietic bone marrow derived cells in psoriatic patients were 
functionally impaired both with regard to cytokine production and suppressive activities 
compared with cells from normal volunteers (208).  
 
1.6. Bronchus associated lymphoid tissue (BALT) 
BALT is defined as organized secondary lymphoid tissue located within the subepithelial 
bronchial lamina propria with overlying lymphoepithelium (209). Early studies found that 
BALT may be present in the human fetal and infant lung (210; 211), but that its appearance 
is probably dependent on antigenic stimulation (212). Thus, it is not regularly present at 
birth but may transiently arise during childhood and adolescence (209). A post-mortem 
study showed that BALT was present in 36.4 % of the patients who had died of SIDS and in 
44.1 % of the control cases (213). Whether BALT is a feature of the normal adult lung has 
not been resolved (214; 215) but is found in various disease states (216). In mice, virus 
infections induce BALT (217; 218). It was demonstrated that antigen-loaded DCs rapidly 
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migrate into BALT and efficiently activate antigen-specific T cells and furthermore, CD11c+ 
DCs were essential for maintaining these structures (218). In a mouse CCR7 knock-out 
model T were shown to inhibit BALT formation (219). In mice lacking regs spleen, lymph 
nodes and Peyer's patches it was shown that inducible BALT generated unexpectedly robust 
primary B- and T-cell responses to influenza virus (220). However, little is known about the 
function of BALT in humans. The early appearance of BALT in neonatal life suggests that 
they may be important in establishing mucosal homeostasis in early life (61). Interest in 
BALT as an inductive site in children is warranted by the potential role of these structures in 
shaping immune responses both in infections as well as in the advent of effective mucosal 
vaccinations (221). 
 
1.7. Effects of UV radiation on the immune system 
Immunosuppressive effects of UV radiation were first described decades ago. Pioneer 
studies by Margaret L. Kripke demonstrated that UV-induced tumors transplanted onto 
normal mice were rejected but when transplanted onto mice treated with 
immunosuppressive drugs or mice exposed to UV radiation the tumors grew (222). 
Immunosuppressive effects have been found both locally and systemically (223; 224). In 
models of CHS, hapten painted on skin areas induces an inflammatory response. However, 
when the painted area is exposed to low doses of UVB radiation, CHS is inhibited (225). 
Higher doses of UV radiation also affect immune responses at distant, non-UV exposed 
sites. CHS cannot be induced in mice exposed to high doses of UV radiation even if the 
contact allergen is applied at an unirradiated site (226). Mechanisms mediating the 
immunosuppressive effects have been shown to include both alterations in cellular activitiy 
as well as the involvement of cytokines. Direct effects on the adaptive immune system 
include induction of apoptosis in lymphocytes (227). Keratinocytes produce the 
immunosuppressive cytokine IL-10 in response to UV radiation, which may act both locally 
and enter the systemic circulation (228). LCs are the best studied DC population in 
photoimmunology. Epidermal depletion of LC in response to UV radiation is primarily due 
to migration to regional lymph nodes (229; 230). LCs are impaired in their ability to present 
antigens through suppression of MCH-II and ICAM-1 expression following UV radiation 
(231). UV radiation has also been shown to downregulate the costimulatory molecules 
CD80 and CD86 on both LCs and blood DCs (232; 233). Dermal DCs were shown to 
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become tolerogenic upon UV exposure (234; 235). Dermal macrophages upregulating IL-10 
and downregulating IL-12 were expanded in response to UV exposure (236). Recently the 
induction of antigen-specific Tregs in response to UV radiation has been documented (237; 
238). Whereas adaptive immune responses seem to be suppressed by UV exposure, 
components of the innate immune system are stimulated. UV radiation activates the 
inflammasome in human keratinocytes, resulting in the processing and release of IL-1 
(239). AMPs like cathelecidin are upregulated in the skin upon UV exposure (240).  
Exposure to UV radiation triggers the conversion of 7-dehydrocholesterol into 
cholecalciferol, or vitamin D, thus increasing vitamin D production (241). Vitamin D has 
multiple modulating effects on the human immune system. Vitamin D inhibits cytokine and 
chemokine production in macrophages (242), thus preventing excessive inflammation, 
whereas their “oxidative burst”, which increases their ability to kill ingested pathogens is 
stimulated (243). Vitamin D increases the production of endogenous AMPs in monocytes, 
neutrophils, and in human cell lines (244-246). Skin DCs metabolizing vitamin D have been 
shown to induce T reg (59). Topically applied vitamin D3 enhances the suppressive activitiy 
of CD4+CD25+ Tregs in draining lymph nodes (247). Mechanisms of UV-induced 
immunosuppression have also been shown to include increased expression of RANKL on 
keratinocytes, which in turn stimulate DCs to induce Tregs (248). One of the primary 
regulators of RANKL is 1,25 (OH) D2 3, the active form of vitamin D, again showing the 
importance of vitamin D in modulating immune responses (249; 250). 
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2. AIMS OF THE STUDY 
The aims of the works presented in this thesis were 
 
 Study the organization of the local immune system in the bronchial mucosa of 
infants and young children related to development of airway obstruction, with 
emphasis on antigen presenting cells 
 Study the early impact of sun exposure on the immunopathology in psoriatic skin, 
with emphasis on antigen presenting cells and T cell populations. 
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3. MATERIALS AND METHODS 
3.1. Subjects 
In paper I the subjects studied were 45 children aged 4-23 months (15 females) under 
clinical evaluation for respiratory disease. They all had symptoms from the respiratory tract 
of significant duration (median 60 % of their lifetime, range 19-100 %). Bronchoscopy was 
performed on clinical indication whereas biopsy sampling was for research purposes. 
Patients were divided into three groups according to their specific airway conductance 
(sGaw) based on results from lung function testing with whole body plethysmography: 1) 
bronchial obstruction with reversibility, 2) bronchial obstruction without reversibility and 3) 
normal lung function. Reversibility was defined as a 30 % increase in sGaw in response to 
inhalation of the 2-agonist salbutamol (251). None of the patients had been treated with 
steroids, either locally or systemically, for the last 6 weeks prior to bronchoscopy. 
In paper II, bronchial specimens obtained at autopsy from nine children aged 1.9 – 
15.4 years (median 8.5) who died from traumatic causes. No evidence of respiratory disease 
or atopic eczema were discovered upon autopsy.  
In papers III and IV 20 patients (median age 48 years, range 24-65, 6 females) 
suffering from psoriasis and eligible to receive heliotherapy, a well established treatment 
modality for psoriasis patients in Norway, were included. They were transported from 
Norway to Gran Canaria, Spain, in the month of March. The patients were evaluated by the 
same dermatologist for the Psoriasis Area and Severity Index (PASI) (252) before and after 
sun treatment. All patients had moderate to severe plaque psoriasis, i.e. mean/median PASI 
before heliotherapy of 9.8/8.7, range 3.8-18.8. All patients had stopped using any psoriasis 
medication at least 4 weeks prior to this study. Two of the patients had skin type II and 18 
had skin type III according to the Fitzpatrick classification and III. UV doses were measured 
during the study period (253). 
 
3.2. Airway biopsies  
Bronchoscopy of patients in Paper I was clinically indicated, whereas mucosal tissue was 
obtained for research purposes. Rigid bronchoscopy, which in the hands of experienced 
operators is as safe as flexible (254), gives a better view on the anatomical structures and 
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allows obtaining somewhat bigger and better preserved biopsies. Written, informed consent 
from parents was obtained and the study was approved by the local Ethics Committee. 
There were no complications associated with the endoscopic procedures. Bronchial biopsy 
specimens were obtained from the carina, formalin-fixed and paraffin-embedded.  
In Paper II, samples were obtained from the proximal main bronchi during autopsy, 
formalin-fixed and paraffin-embedded. 
 
3.3. Skin biopsies 
In Papers III and IV, 4 mm punch biopsy samples were collected from lesional and non-
lesional skin in 10 randomly selected patients to evaluate the effect of sun exposure on the 
local inflammatory infiltrates. The samples from each individual patient were obtained 
within the same body area at different time points, in sufficient distance to avoid a reactive 
inflammation from prior biopsy sampling. Specimens were either formalin-fixed and 
paraffin-embedded or snap frozen in liquid nitrogen and stored at -80 C until sectioning.  
 
3.4. Immunohistochemistry 
Immunohistochemistry (IHC) is a robust method of identifying antigens (primarily proteins)
in situ in tissue sections (255). In this method specificity is achieved by applying (mostly) 
monoclonal antibodies obtained from animals which were immunized by the antigen in 
question. Tissue sections may be formalin-fixed and paraffin-embedded or frozen in liquid 
nitrogen, socalled cryosections. Fixation of tissue in formalin induces protein-protein and 
protein-nucleic acid cross-linking by formation of methylen-bridges (256). This contributes 
to preserving the morphology of the tissue, but may render antigen inaccessible to Ab 
binding, socalled “masking”. Formalin-fixed and paraffin-embedded specimens need to be 
deparaffinized prior to staining. Additionally, boiling of sections is often helpful, socalled 
“antigen retrieval” (256). In cryosections the microanatomy is often less well preserved, but 
staining procedures are quicker and antigen masking is less problematic. Frozen samples are 
placed in a medium called Optimum Cutting Temperature (OCT) for sectioning and fixated 
in acetone or ethanol before staining. 
Several methods for detection of bound antigen in tissue sections exist. Antibodies 
may be labeled with fluorochromes, which require visualization in a fluorescence 
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microscope. The antibody recognizing the antigen is called primary antibody and may be 
monoclonal (recognizing a single epitope or part of the antigen) or polyclonal (recognizing 
several epitopes). Primary antibodies may be derived from different species (eg. mouse and 
rat) and be of different Ig subclasses. The different properties of the primary antibodies 
allows for different mechanisms of detection. After incubating the tissue section with a 
primary antibody, a secondary antibody is applied, which will interact with the primary 
antibody, either by using an antibody reacting with immunoglobulin from the specific 
animal or from the immunoglobulin subclass. Conjugating the secondary antibody with 
fluorescent molecules, allows visualization of the bound antibody complexes in a 
fluorescence microscope. Applying primary antibodies of different subclasses (or species) 
and subclass (or species) specific secondary antibodies with different fluorochromes allows 
detection of two or three different antigens in the same section (Figure 8). 
 
 
 
Cell
AAB B
Primary antibody of the subclass IgG1
recognizing antigen A
Primary antibody of the IgG2a subclass 
recognizing antigen B
Fluorescent secondary antibody recognizing 
primary antibody of the IgG1 subclass
Fluorescent secondary antibody recognizing 
primary antibody of the IgG2a subclass
Figure 8. During incubation with the specific primary antibodies, these bind to their respective epitopes.  
 
The subsequent application of species- or subclass specific secondary antibodies labeled with different 
fluorochromes allows detection of several antigens in the same section. 
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Biotin and the bacterium-derived molecule streptavidin form the strongest non-covalent 
binding known in the field of biology (257) and this is utilized for enhancing signals in IHC. 
Streptavidin may be coated with fluorochromes and applied subsequently to incubating 
sections with biotin-labeled primary or secondary antibodies (Figure 9). 
 
 
Cell
AAB B
Primary antibody of the subclass IgG1
recognizing antigen A
Biotinylated secondary antibody recognizing 
primary antibody of the IgG1 subclass
Fluorescent streptavidin binding to biotin
Cell
AAB B
 
Figure 9. The secondary antibody is biotinylated, allowing for the specific binding of streptavidin labeled 
with fluorochome in a third step. In tissues with high natural biotin contrent endogenous biotin must be 
inhibited. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 32 
MATERIALS AND METHODS 
 
                                 
In immunoenzyme staining the secondary antibody is conjugated with an enzyme, eg. 
peroxidase or alkaline phosphatase (ALP). After incubation steps with the primary and 
secondary antibodies, substrate is added, which will then change color due to the enzymatic 
activity and give a staining of the section, allowing visualization by a normal light 
microscope (Figure 10).  
All staining procedures must be performed after careful titration of both primary and 
secondary antibodies. Positive controls ensure that the staining procedure works and 
negative controls with irrelevant primary antibodies ensure staining specificity.  
 
Cell
Primary antibody of the subclass IgG1
recognizing antigen A
Primary antibody of the IgG2a subclass 
recognizing antigen B
Enzymatically labelled secondary antibody 
recognizing primary antibody of the IgG1 
subclass
Biotinylated secondary antibody 
recognizing primary antibody of the IgG2a 
subclass
Cell
AAB B
Substrate for enzyme
Substrate for enzyme
Product visualized in light microscope
Product visualized in light microscope
Enzymatically labelled streptavidin 
Binding to the biotinylated secondary 
antibody
 
Figure 10. Immunoenzyme staining. The secondary antibody is conjugated with an enzyme (right). After 
application of the appropriate substrate, a chromogen, will leave a coloured precipitate in the section, which is 
visible in light microscope. The secondary antibody may also be biotinylated (left) and a different enzyme may 
be conjugated to streptavidin. Thus requires a fourth step in the staining protocol, but allows for double 
staining of a section. 
 
 
Both formalin-fixed paraffin-embedded and cryo-preserved specimens were cut at 4μm and 
stained with antibodies for IHC. Examination of dewaxed formalin-fixed sections in Papers 
I and II was performed by immunoenzyme staining in a Ventana NexEs IHC instrument 
(Tucson, AZ) with the standardized iView DAB or enhanced V-Red (alkaline phosphatase) 
detection kits as recommended by the manufacturer. For optimal staining results in 
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formalin-fixed sections that were not stained in the Ventana instrument, heat-induced 
antigen retrieval was performed by boiling the sections in a microwave oven for 20 min in 
citrate buffer (pH 6.0) prior to application of antibodies. The primary monoclonal antibodies 
(mAbs) were directed against human HLA-DR, CD68, CD1a, CD123, CD3, CD20, 
CD45RA, CD11c and MECA (the latter three only in paper II).  
Paired immunofluorescence staining was performed with a polyclonal rabbit anti-
CD3 antibody and a rat mAb to Foxp3, followed by Alexa Fluor 488 goat anti-rabbit IgG 
and Cy3-conjugated donkey anti-rat IgG. Appropriate isotype- and concentration-matched 
control reagents ensured immunostaining specificity. 
Cryopreserved sections were fixed in acetone and kept at -70° until sectioning. In 
paper III, hematoxylin-eosin (HE) stained sections were evaluated for changes in epidermal 
thickness. Two-colour immunofluorescence staining was performed combining rabbit 
polyclonal anti-CD3 with mouse anti-CD4, mouse anti-CD8 or mouse anti-FOXP3. Staining 
for LCs was performed with anti-CD1a. The primary antibodies were followed by 
fluorescence-labelled secondary antibodies: Alexa 488 goat anti-rabbit IgG or Cy3 goat 
anti-mouse IgG. 
In paper IV, fluorescence immunostaining of APC populations was performed by 
costaining sections with mouse anti-human mAbs. Costaining of CD11c and HLA-DR was 
performed with anti-CD11c (IgG1) and anti-HLA-DR (IgG2a) followed by a biotinylated 
rat anti-mouse IgG2a antibody and then Cy2-conjugated streptavidin and Cy3-conjugated 
rat anti-mouse IgG1. Costaining of CD11c and other markers was performed with anti-
CD11c (IgG2a) and CD1c, CD163, CD14, DC-SIGN or DC-LAMP (all IgG1), followed by 
biotinylated rat anti-mouse IgG2a and Cy3-conjugated rat anti-mouse IgG1.  
 
3.5. Microscopy 
All stained tissue sections were examined blindly by the same investigator (IH) at x 400 
magnification using an ocular grid (250μm x 250μm). In papers I and II, the cell density in 
the respiratory epithelium was recorded as the total number of positive cell profiles per 
basement membrane length unit (1 mm), whereas the cell number in lamina propria was 
recorded as positive cell profiles per square millimeter. The mucosal areas containing 
lymphoid aggregates were omitted from the cell enumeration.  
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In papers III and IV, cell numbers were recorded, counting positive cell profiles in 
epidermis and in the papillary and reticular dermis, to a depth of 250 μm. For the grossly 
thickened epidermis of psoriatic lesions, cell numbers per square millimetre rather than per 
millimetre of surface epidermis will reflect the cell density more accurately. Data for both 
dermal and epidermal cell counts are given as cells numbers per square millimetre, in both 
lesional and non-lesional skin, in order to make comparisons.  
For quantification of epidermal MxA-staining (Paper III), an arbitrary scale from 0 
through 5 was established in order to grade the intensity.  
 
3.6. Flow cytometry 
Flow cytometry is a method in which single cell suspensions are incubated with monoclonal 
antibodies specific for cell surface markers expressed in different cell populations. Binding 
of mAbs may be detected with fluorescent secondary antibodies analogous to IHC. A step 
containing biotin-streptavidin binding may be included. Alternatively, primary antibodies 
may be directly conjugated with fluorochromes. Cells are analysed in a flow cytometer in 
which single cells are exposed to laser beams and fluorescence signals are detected. Signals 
regarding cell size and granularity are also detected and data are analyzed by the flow 
cytometer software.  Staining is always compared with negative controls samples, i.e. 
samples in which non-binding primary antibodies are applied, ensuring specificity of signals 
obtained. 
In order to examine effects of heliotherapy on circulating T cell populations, blood 
was drawn from all patients on days 0, 2 and 16 of sun exposure (paper III). EDTA-whole 
blood was incubated with monoclonal antibodies against leukocyte (CD45) and T-cell 
markers (CD3, CD4, CD8 and CLA) directly conjugated with the fluorochromes fluorescein 
isothiocyanate (FITC), phycoerythrin (PE), peridinin chlorophyll protein (PerCP) and 
allophycocyanin (APC). Negative control samples were stained with isotypic-matched 
irrelevant antibodies. After 20 minutes at room temperature in the dark, erythrocyte lysis 
was performed. Samples were then washed in PBS and cells were examined by flow 
cytometry. At least 10.000 lymphocytes were gated by forward and side scatter and CD45 
expression. The collected data were analyzed using CellQuest Pro software (Apple 
computer, Inc; Cupertino, CA).  
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3.7. Cell culture and cytokine measurements 
In Paper III, venous blood samples were collected from all 20 psoriasis patients on days 0, 2 
and 16 for investigation of effects on immune cells in the systemic compartment. Peripheral 
blood mononuclear cells (PBMCs) obtained from heparinized blood by isopaque-Ficoll 
gradient centrifugation were incubated in flat-bottomed 96-well trays at 2x106 cells/mL; 100 
μL/well in medium alone (RPMI-1640 containing 2 mM L-glutamine, supplemented with 
100 U/mL penicillin and 5% fetal calf serum), or with phytohaemagglutinin (PHA; final 
concentration 5 μg/mL). Cell-free supernatants were harvested after culturing for 24 hours 
and stored at -80oC until analysis. 
IL-12p40, IFN-, IL-17, TNF- and IL-10 from culture supernatants were measures 
using a commercial multiplex cytokine assay (Bio-Plex Human Cytokine 8-Plex Panel, Bio-
Rad Laboratories Inc., Hercules, CA) according to the manufacturers instructions.  
3.8. RT-PCR 
Polymerase chain reaction (PCR) is a method in molecular biology used to amplify a single 
or few copies of a piece of DNA across several orders of magnitude, generating thousands 
to millions of copies of a particular DNA sequence (258). Primers (short DNA fragments) 
containing sequences complementary to the target region and the enzyme DNA polymerase 
(after which the method is named) are the key components that enable selective and 
repeated amplification. As PCR progresses, the DNA generated is itself used as a template 
for replication, thus initiating a chain reaction in which the DNA template is exponentially 
amplified. In order to evaluate the production of a given protein in cell or tissue samples, 
measurement of mRNA is often used in addition to detecting the protein directly via IHC. 
To detect mRNA, DNA complementary to the RNA socalled cDNA must be generated first, 
using the enzyme reverse transcriptase (RT). Thus, the method is called RT-PCR (258). 
In Paper III RNA was isolated from cryosections obtained from 5 patients before, 
after 1 day and after 16 days of sun exposure and subjected to examination by RT-PCR, in 
order to evaluate the local expression levels of cytokines. The primers applied were specific 
for mRNA for TNF-, IL-12p40, IL-23p19, IL-17A, IL-10 and TGF-. See Paper III for 
further details. 
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3.9. Statistical analyses 
Non-parametric analyses were applied in all papers.  In Paper I, for analysis of between-
group differences the Kruskal-Wallis and Mann-Whitney tests were applied. For 
correlations, the Spearman’s rank-order coefficient was used. In Paper III the paired 
Wilcoxon signed rank test was used to examine differences within the same individuals over 
time and in Paper IV, three time points within the same individuals were analysed with the 
Friedman’s test. In both papers, analyses of PASI-scores were performed with the 
parametric Student’s t-test. P<0.05 were interpreted as significant.  
SPSS 12.0.1 for windows (Chicago, IL) and GraphPad Prism 4 (San Diego, CA) 
were used for the statistical analyses. 
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4. SUMMARY OF RESULTS 
Paper I
Heier I, Malmström K, Pelkonen AS, Malmberg LP, Kajosaari M, Turpeinen M, 
Lindahl H, Brandtzaeg P, Jahnsen FL, Mäkelä MJ.  
Bronchial response pattern of antigen presenting cells and regulatory T cells in 
children less than 2 years of age. Thorax. 2008 Aug;63(8):703-9.  
 
46 children under investigation for respiratory symptoms, aged 4-23 months, were included 
in this study. They were divided into three different groups based on clinical presentation, 
i.e. reversible airway obstruction, irreversible airway obstruction or no bronchial 
hyperreactivity. Mucosal biopsy specimens from the carina were obtained during 
bronchoscopy. By immunohistochemistry, we performed detailed characterization of the 
local immune system. We found a well developed extensive network of APCs both within 
and beneath the surface epithelium. The density of APCs in the lamina propria correlated 
positively with increasing age. Some APCs extended their dendrites into the airway lumen, 
as has been previously shown in the gut mucosa. We found BALT in nearly half of the 
individuals, suggesting that local inductive sites are a normal feature of infant airways. We 
found no differences in distribution of APC subsets or BALT between the three different 
clinical groups.  
 
Paper II
Heier I, Malmstrøm K, Lohi J, Sajantila A, Mäkelä MJ, Jahnsen FL.  
Characterization of bronchus-associated lymphoid tissue and antigen presenting cells 
in central airway mucosa of children.  
Manuscript 
 
Here, we studied bronchial specimens obtained post-mortem from nine children aged 2-15 
years who died from non-inflammatory causes without signs or history of respiratory 
disease. Total numbers of APCs and macrophages were comparable to what we previously 
found in Paper I. In contrast to observations in infants less than 2 years old, there was no 
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correlation between age and cell numbers, indicating that steady-state numbers have been 
achieved. In all nine individuals isolated subepithelial lymphoid follicles interpreted as 
BALT, in which myeloid DCs, B cells, naïve T cells as well as pDCs accumulated. pDCs 
were also found throughout the lamina propria.  In conclusion, we show that the density of 
APCs previously described in infants and younger children remains throughout childhood 
and that a steady-state level are reached at approximately 2 years of age. BALT is a feature 
of normal airway mucosa throughout childhood.  
Paper III
Søyland E *, Heier I *, Rodríguez-Gallego C, Mollnes TE, Johansen F-E, Holven KB , 
Halvorsen B, Aukrust P, Jahnsen FL, Krogstad A-L and Nenseter MS.  
Sun Exposure Induces Rapid Immunological Changes in Skin and Peripheral Blood in 
Psoriasis Patients.   
Paper submitted. 
*These authors share first authorship 
 
In this study, we examined immunological parameters in 20 patients with moderate to 
severe psoriasis, who underwent heliotherapy for 16 days on Gran Canaria. We performed 
immunohistochemistry on biopsy specimens from 10 patients obtained at baseline and on 
day 16 of sun exposure and from an additional 5 patients on day 2. Biopsies were obtained 
from both lesional and non-lesional skin. We detected a rapid decline in lymphocyte 
numbers from both the epidermal and dermal compartments with both CD4+ + and CD8  T 
cells being significantly reduced after 16 days. In contrast, the number of dermal FOXP3+ T 
cells, i.e. putative Tregs, remained unchanged, suggesting a relative increase in this cell 
population. The density of epidermal LCs was markedly reduced in lesional compared with 
non-lesional skin and was only modestly reduced after sun exposure. In non-lesional skin, as 
expected, LCs were dramatically reduced in response to sun. In peripheral blood, the 
number of CLA+ T cells decreased significantly after only 1 day in the sun and remained 
reduced at day 16. At day 16, PHA-stimulated PBMCs released significantly reduced levels 
of pro-inflammatory cytokines. Skin biopsies were examined by RT-PCR for expression of 
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cytokine mRNA and reduced levels of IL-12 and IL-23 were found at day 16. Together, our 
data showed that sun treatment had systemic as well as local immunomodulatory effects. 
 
 
Paper IV
Heier I, Søyland E, Krogstad A-L, Rodríguez-Gallego C, Nenseter MS, Jahnsen FL. 
Sun Exposure Rapidly Reduces Plasmacytoid Dendritic Cells and Inflammatory 
Dermal Dendritic Cells in Psoriatic Skin.   
Paper submitted 
 
In this study, we examined biopsy material from the same patients as in paper III, with 
emphasis on dermal APC subpopulations. We found increased numbers of pDCs in lesional 
skin, which were significantly reduced after 16 days of sun exposure. The surrogate marker 
for IFN-, MxA, was also reduced at day 16, suggesting that sun had an inhibitory effect on 
IFN- production, most likely produced by pDCs. Further, in lesional dermis, the putative 
inflammatory CD11c+CD1c- myeloid DC was 20-fold increased compared with non-lesional 
dermis. This subpopulation was selectively reduced in lesional skin upon sun exposure, 
whereas the percentage of CD11c+ +coexpressing CD1c  increased. CD163+ + and DC-SIGN  
macrophages were twofold increased in lesional dermis and decreased significantly upon 
sun exposure. The percentage of CD11c+ DCs expressing the activation marker DC-LAMP 
(CD208) was significantly decreased in lesional dermis during sun exposure. A substantial 
proportion of CD11c+ DCs in lesional dermis coexpressed the macrophage markers CD163 
and DC-SIGN, whereas no CD1c+ DCs coexpressed these markers. No overlap in the 
expression of CD11c and CD163 was seen in non-lesional skin. 
In conclusion, sun exposure resulted in rapid reductions in APC subpopulations 
believed to be involved in mediating psoriasis pathogenesis, probably contributing to the 
clinical improvement observed.  
 
 
 
 
 
 41
SUMMARY OF RESULTS 
 
                                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 42 
GENERAL DISCUSSION 
 
                                 
5. GENERAL DISCUSSION
APCs and T cells activated by them are central players in both TH2-dominated disorders like 
asthma and TH1/TH17-dominated autoimmune disorders like psoriasis. The aim of this work 
was divided into two related sub-aims. First, we wanted to examine how the immune system 
was organized in the bronchial mucosa of infants and young children with special emphasis 
on APCs and investigate whether cell subsets differed in children with or without atopy-
related respiratory disease. Next, we wanted to examine the early impact of sun exposure in 
psoriasis, with respect to APC and T cell populations locally and in the systemic 
compartment.  
During pregnancy, the fetus develops in a sterile environment and the immune 
system is immature and skewed towards TH2-responses (259-261). The first years of 
postnatal life is important in modeling the maturing adaptive immune system (142). 
Antigenic exposure results in TLR-stimulation and a gradual increase in TH1 responses, 
whereas the tendency to mount TH2 responses is gradually reduced. Thus, this period 
represents a window of susceptibility, in which allergic sensitization can take place (142). 
The TH2-inducing properties of many aeroallergens are well described, and additional 
genetic susceptibility factors as well as viral infections may contribute to the development 
of an allergic phenotype (262). Respiratory syncytial virus (RSV), a common airway 
pathogen which infects more than 90 % of children before the age of 2, has been shown to 
induce a TH2 response (263), which in susceptible individuals may contribute to the 
development of recurrent wheezing (264). The TH2-dominated atopic disorders, among 
which asthma is the most severe, are initiated through the activity of APCs, first of all by 
DCs through their unique capacity to activate and polarize naïve T cells (152). The 
occurrence and function of mucosal APCs, and DCs in particular, could therefore play a role 
in the vulnerable first years of life. 
In Paper I, examining airway biopsies from 45 children 4-23 months of age, we 
found that the number of mucosal APC, defined as HLA-DR+ cells was significantly 
correlated with increasing age. Further characterization of the APC population showed that 
approximately 50 % were CD68+ macrophages whereas the remainders were putative DCs. 
Others have reported very low numbers of APCs in the airway mucosa in the first year of 
life (136; 265), making it likely that APCs gradually populate this compartment postnatally 
in response to antigenic stimulation. The study subjects were divided into 3 groups based on 
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clinical findings, i.e. bronchial obstruction with or without reversibility or normal lung 
function, with the hypothesis that these clinical groups might differ with respect to numbers 
and/or distribution of APC subsets. However, no differences could be found between these 
groups, nor between atopics or non-atopics. The patients studied here were very young and 
making a certain diagnosis of asthma in this age group is problematic (264). Follow-up of 
these children to examine whether differences in airway mucosal cell densities would be 
reflected in different clinical phenotypes at a later stage would therefore be warranted.  
The numbers of CD1a+ intraepithelial DCs were found to be significantly increased 
in the patients who had suffered a recent respiratory infection (Paper I), suggesting an 
increased influx of cells due to inflammatory stimuli. Infection with Human rhinovirus 
(HRV) is a well known inducer of asthma exacerbations (266), but we found no correlation 
with cell numbers in patients with or without HRV positivity on PCR.  
All individuals in Paper I were suffering from respiratory disease and biopsies were 
obtained on clinical indication. For obvious ethical reasons airway biopsies cannot be 
obtained from healthy children as controls, therefore, we examined airway tissue from 
children who had died from non-infectious causes and who had no history or signs of airway 
disease or atopy (Paper II). Although the subjects were older (2-15 years), total numbers of 
HLA-DR+ cells were similar to that found in Paper I, with similar fractions of macrophages 
and putative DC subsets. No correlation between age and numbers of APCs was found in 
this population. Although the number of patients included in paper II was relatively low 
(n=9), it seems plausible to propose that the density of airway mucosal APC increases until 
approximately 2 years of age, and then reaches a steady-state. At approximately 2 years of 
age the immune system has been shown to become more mature with respect to several 
parameters (267; 268). 
Paper I showed that 50 % of the small biopsies from bronchial mucosa of children 4 
to 23 months of age contained BALT. Importantly, in Paper II, using autopsy material we 
found that BALT was more common and occurred in much higher densities than previously 
anticipated. Our findings strongly suggest that BALT is a normal feature of central airway 
mucosa also in older children. Little is known about the function of BALT in humans, but in 
mouse models isolated mucosal lymphoid follicles have been shown to be sufficient for the 
induction of protective immunity against influenza virus infection (220). We defined BALT 
as cellular aggregates dominated by CD45RA+ + cells (a marker of naïve T cells), CD20  B 
cells, CD11c+ DCs and some relatively few but predictable pDCs. In some of these 
structures we also detected HEVs (MECA-79+ +). Also, FOXP3  T were found primarily regs 
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within these lymphoid structures, although a few were also found scattered in the LP (Paper 
I). Most functional immunological studies have emphasized the importance of DCs 
migrating to the draining lymph nodes to prime the adaptive immune system. Here, we 
show that naïve T and B cells are found together with DCs as organized lymphoid tissue just 
beneath the epithelial surface at high densities. This may suggest that immune responses to 
aereoantigens in infants may be initiated to a large extent locally and partly independent of 
lymph node involvement. These structures should therefore be taken into account when 
studying the airway immune system in infants and its importance for health and disease.  
How DCs capture antigens at human mucosal surfaces has not been determined. In 
papers I and II we demonstrate that intraepithelial APCs send cellular projections between 
epithelial cells onto the luminal side. In mouse models it has been shown that these 
“snorkeling” DCs capture luminal antigens in the airways (138) and in the gut (269). This 
unique intraepithelial position enable airway DCs to directly sample antigens from the 
lumen and then transport this material to secondary lymphoid tissue for presentation to T 
cells. Together, our findings suggest that at least two major routes for uptake of 
aeroantigens should be taken into consideration; both uptake via BALT and via 
“snorkeling” APCs.  
pDCs have been shown to be vital to the induction of tolerance towards 
aeroallergens in mouse models (79; 163) and low numbers of circulating pDCs were 
recently found to be associated with a higher risk of recurrent respiratory tract infections 
and wheezing in children (164). We describe here for the first time the presence and 
distribution of pDCs within airway mucosa of children. The finding of pDCs and Tregs 
primarily within the inductive sites of the bronchial mucosa, suggest that these cells may 
contribute to inducing tolerance to environmental allergens, thus playing a role in immune 
homoeostasis in childhood.  Understanding the regional airway mucosal immune system is 
vital to the work on developing more effective site-specific vaccines for children (8; 221). 
 
Psoriatic lesional skin is densely infiltrated with inflammatory cells. T cells of the 
TH1 and TH17 phenotypes are widely recognized as important effector cells, but infiltrating 
DC subsets and macrophages are also central to the immunopathology (Figure 6). In Papers 
III and IV, we describe rapid effects of sun exposure on immunologic parameters, both 
locally and systemically. Determining the cell densities at three time points during sun 
exposure (baseline, days 2 and 16), we observed reduction in both CD8+ + and CD4  T cells 
in lesional skin already at day 2 (Paper III). This reduction was most pronounced in the 
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intraepithelial CD8+ subpopulation and presumably primarily due to induction of apoptosis 
(227; 270). In order to examine the specimens for evidence of apoptosis, we stained for 
cleaved caspase-3, but could not detect any positive signals, in spite of good results in 
positive control samples. We speculate that one explanation for this could be due to timing 
and that the product of apoptosis detected by this method may not be optimally expressed at 
the time points on which our biopsies were sampled. 
This reduction in T-cell numbers was paralleled by a reduction in mRNA levels of 
primarily IL-12p40, IL-23 and IL-17. The decrease in mRNA levels was non-significant due 
to low number of samples but suggested that cytokines associated with the IL-23/TH17-axis 
were reduced, as has been demonstrated in several previous studies (48). The increased IL-
10 mRNA levels in lesional skin in 3 out of 4 individuals at day 16 also supports the 
concept of a change from an inflammatory into a more homeostatic environment upon sun 
exposure.  
We found that the density of epidermal LCs was significantly reduced in psoriatic 
skin at baseline (Paper III), in line with previous reports (194). Others have reported normal 
densities of LCs and discrepancies could possibly be explained by different methods of 
enumerating cells (97). LCs in non-lesional epidermis were near depleted after sun 
exposure, as expected (230). In contrast, epidermal LCs in lesional skin were only modestly 
although significantly reduced, a finding that supports the concept that UV-induced 
migration may be impaired in psoriasis (195). LCs have been implicated in tolerance 
induction which suggests that this impaired migratory function of LCs in psoriasis, could 
contribute indirectly to the pathogenesis. However, as LC migration in non-lesional skin 
was intact, this does not seem to be a primary defect in psoriasis patients, but may be a 
secondary phenomenon in psoriatic skin.   
Among cutaneous DCs, epidermal LCs is the best studied subset with respect to the 
immunosuppressive effect of UV therapy (223). However recently, it was shown in a mouse 
model of contact hypersensitivity that dermal DCs were essential for UV-induced 
suppression in the absence of LCs (235). We confirmed previous reports that CD11c+ -CD1c  
DCs were dramatically (20-fold) increased in psoriatic lesional dermis. This cell population 
has been found to represent an inflammatory subset, that accumulates in psoriatic lesions, 
produces TNF- and iNOS and induces TH1/TH17 cells (186; 187). Importantly, we found 
that these cells were rapidly and selectively decreased upon sun exposure (i.e. the total 
number of CD11c+ cells was not significantly changed), with marked reductions in cell 
densities already after 1 day in the sun (Paper IV), strongly suggesting that this subset is 
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+central in immunopathogenesis. Simultaneously, the percentage of CD11c  DCs 
coexpressing CD1c increased significantly, thus creating conditions more similar to that 
found in non-lesional skin. This shows that sun exposure affects several populations of 
immune cells and suggests that the selective reduction in inflammatory DCs is one of the 
immunosuppressive mechanisms of UV-exposure. 
Whereas pDCs are associated with antiviral immunity and immune homeostasis in 
the airways, their accumulation in the skin is associated with autoimmune pathology in both 
psoriasis (77; 182) and lupus erythematosus (76; 271), with unregulated production of IFN-
 believed to play a central role. We report, to our knowledge, for the first time that the 
density of pDCs, as well as expression of MxA, was rapidly reduced in psoriasis upon sun 
exposure. This reduction preceded clinical improvement, further underscoring the 
pathogenic role of pDCs (Paper IV). However, the seemingly paradoxical finding that in 
non-lesional dermis, sun exposure resulted in increased numbers of pDCs, but with no 
concurrent increase in MxA or signs of inflammation, suggests that these cells may also 
have an immunomodulatory effect in the skin.  
+FOXP3  Tregs are vital in maintaining immune homeostasis and have been shown to 
be impaired in number and function in psoriasis (205). FOXP3+ cells were increased in 
lesional skin along with the other major cell populations (Paper III), which may support the 
concept of a reduced function but not recruitment in this disease (205). Epidermal FOXP3+ 
cells were near depleted along with the two main cell subsets.  In contrast, dermal FOXP3+ 
T cells remained unchanged after 16 days of sun exposure, suggesting that the induction of 
Tregs is one of the mechanisms mediating sun induced improvement in psoriasis. A possible 
explanation for the differential effect on FOXP3+ T-cell numbers in the two compartments 
could be that the dermal cells are less susceptible to apoptosis and that newly recruited Tregs, 
reflecting a change in the local cytokine milieu, will be found in the dermis under such 
circumstances. However, FOXP3 has also recently been shown to be transiently induced in 
activated effector T cells (125), and functional analysis of these cells in psoriatic skin would 
have to be performed in order to show that FOXP3+ T cells in the dermis are truly functional 
T . regs
Sun exposure has been shown to have significant impact on various components of 
the immune system (223). At the systemic level, we also demonstrate that skin homing 
CLA+ +CD4  and CLA+CD8+ T cells in peripheral blood decreases significantly in psoriatic 
patients after only one day of sun exposure (Paper III). Previously, it has been shown that 
UVB exposure reduces total CLA+ T cells in the blood of psoriatic patients after one week 
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(272). The rapid decrease of CLA+ T cells in peripheral blood could be caused by an 
increased migration to the skin as a result of non-specific low-level inflammation after acute 
sun exposure. However, cell numbers in non-lesional skin were unchanged whereas they 
were markedly reduced in lesional skin after sun exposure. As CLA+ T cells preferentially 
circulate to the skin, they become susceptible to apoptosis and thus peripheral numbers 
would decrease. We hold this to be the most likely explanation for the observed rapid 
reduction in circulating skin homing T cells. In Paper III, we also provide evidence of 
functional immunosuppression in the systemic compartment, through the attenuated 
capacity of in vitro-cultured PBMCs to produce cytokines after sun exposure. However, in 
the systemic compartment, we demonstrate decreased production of both proinflammatory 
and anti-inflammatory cytokines. One explanation for this could be that downregulation of 
proinflammatory cascades in the systemic compartment also results in less stimulation of 
compensatory immunosuppressive pathways. This would argue against a role of IL-10 in the 
systemic immunosuppression seen after sun exposure (224; 273). The patients in this study 
had increased vitamin D levels, which may have contributed to immunomodulation (274; 
275). 
Biological agents have received much attention in the treatment of severe psoriasis. 
While therapeutic monoclonal antibodies are effective, their use is expensive and long-term 
data on safety are still lacking (276). Recently, it was shown that etanercept (TNF receptor-
immunoglobulin fusion protein) had a significant effect on psoriasis by inhibiting the 
activity of dermal DCs (189). Importantly, we show here, that sun treatment has at least 
comparable effect with two weeks of etanercept treatment based on the reduction of PASI-
score, epidermal thickness, CD11c+ + DCs, CD163  macrophages, CD3+ T cells, MxA 
expression, DC-LAMP expression and IL-23 mRNA. 
Warm climate and bathing in combination with sun exposure might reduce stress and 
thereby indirectly improve the psoriasis lesions in addition to the UV-induced effects. 
However, there is a large body of evidence to suggest that UV exposure under experimental 
conditions have a very strong immunosuppressive effect, which is compatible with the 
notion that the reduction in pathogenic DCs and T cells observed in lesional skin in our 
study was mainly due to sun exposure. 
An additional finding in our study was that in inflamed skin a large proportion of the 
CD11c+CD1c- + but not CD11c CD1c+ DCs coexpressed monocyte/macrophage markers. 
This further underscores the relative immaturity of these inflammatory DCs (186). In 
normal non-inflamed dermis CD11c+ + mDCs and CD163  macrophages are distinct 
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populations (135), whereas in psoriatic skin, double positive cells accumulate (Paper IV). In 
the upper airways (134) as well as in the gut (Jahnsen FL, unpublished data) there is 
considerable overlap between macrophage and DC markers also under non-inflammatory 
conditions. To a lesser extent we found coexpression of DC and macrophage markers in 
non-inflamed lower airways (Paper II). The turnover of mucosal APC populations is higher 
in the steady-state than in the skin (87; 93), presumably due to the higher antigen 
stimulation. Whereas the skin is protected from the environment by the multilayered 
cornified epidermis, the mucosae are only separated from the surroundings by a single cell 
layer (gut and lower airways) or a multilayered but non-cornified (upper airways). Cells 
expressing markers associated with both DCs and macrophages are found in the circulation 
(277), and may represent precursors en route to peripheral tissue. The risk of both infections 
and allergic sensitization is high at mucosal surfaces. In cases with epidermal breach of 
barrier, as seen in atopic dermatitis, the same is true for the skin (278).  
Maintaining immunological homeostasis in mucosal tissues and the skin, i.e. 
avoiding allergic and excessive inflammatory responses, is a task which to a large extent 
rests with the APC populations as upstream activators of T cells. The studies presented here 
contribute to understanding the regional immune mechanisms both in the airways and in the 
skin.   
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6. CONCLUSIONS
 Infants have a well developed network of APCs in their bronchial mucosa with 
pDCs primarily present within the BALT 
 APCs in the respiratory tract mucosa increases significantly with age but seems 
to reach steady state levels at approximately 2 years of age 
 No differences could be found in the numbers or distribution in these populations 
with respect to clinical phenotype 
 BALT, including T  and pDCs are present at a very early age regs
 Clinical improvement as a result of sun exposure in psoriasis is preceded by 
early rapid changes in CD4+ + and CD8  T cells, with a relative increase in dermal 
T  regs
 Sun exposure rapidly and selectively reduces pDCs and putative inflammatory 
mDCs whereas the percentage of DCs associated with homeostasis increases  
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ABSTRACT 
Childhood represents an immunological window of vulnerability in which individuals are at 
increased risk for both serious infections and development of allergic diseases, particularly 
in the airways. This relative failure in immune regulation in the airways  
may be due to functional differences at the level of the local mucosal immune system. 
However, little is known about how the airway mucosal immune system is organized and 
functions during early age. Here, we characterized the organization of immune cells in 
bronchial mucosal specimens obtained post-mortem from nine children aged 2-15 years 
without signs of respiratory disease who died from non-inflammatory causes. In all nine 
cases isolated subepithelial lymphoid follicles (ILFs) interpreted as bronchus-associated 
lymphoid tissue (BALT) were found constituting an average frequency of 60 ILFs per cm2 
mucosa. Outside these ILFs dense networks of CD11c+ myeloid DCs, CD68+ macrophages, 
and CD3+CD45RA- memory T cells were found both within and beneath the surface 
epithelium. Plasmacytoid DCs also occurred in low numbers. Importantly, intraepithelial 
antigen presenting cells were found to extend cellular projections into the airway lumen. In 
conclusion, we show that the density and location of antigen presenting cells and T cells are 
similar to that observed in adults. However, in contrast to adults, BALT appears to be a 
normal feature of the airway mucosa throughout childhood, suggesting that these structures 
contribute to regional immunity and homeostasis. Our findings thus indicate that the local 
immune system in the airways of children have unique features which should be taken into 
account when studying its role in relation to respiratory immunopathology. 
 2
INTRODUCTION
The respiratory tract has a large mucosal surface that is continuously exposed to a range of 
antigens, both pathogenic microbes and innocuous material, like dust and pollen. The local 
immune system therefore faces a considerable challenge in order to discriminate between 
pathogenic antigens that merit rapid elimination and harmless ubiquitous antigens which 
need to be “tolerated” to avoid chronic inflammatory damage (1). Epidemiological studies 
have shown that in preschool years individuals are more susceptible to both respiratory viral 
infections and aeroallergen sensitization than later in life (2; 3). These findings suggest that 
there is a relative dysfunction of the airway immune system during the first years of life. At 
birth the adaptive immune response appears to be attenuated and skewed towards 
production of Th2 cytokines with a relative inability to produce TH1 immunity (3). This 
postnatal TH1/TH2-imbalance may predispose for development of TH2-dependent allergic 
immunopathology and at the same time increase the risk for viral infections due to 
inappropriate TH1-responses. However, although there is a TH2-skewing in early life, the 
majority of infants do not become sensitized to inhaled antigens, showing that effective 
regulatory mechanisms exist (4). This suggests that there may be functional differences at 
the level of the local mucosal immune system in the respiratory tract. However, little is 
known about how the airway mucosal immune system is organized and functions during 
early age (1). 
Mouse models have shown that airway mucosal dendritic cells (AMDCs) are the 
main inducers of adaptive immunity in the respiratory tract (1; 5).  They are strategically 
situated at mucosal surfaces where they continuously sample antigen from the environment. 
Antigen-bearing AMDCs continuously migrate to the draining lymphoid nodes were they 
present antigenic material to naïve T cells and initiate productive immune responses (5; 6). 
AMDCs consist of several subsets which are functionally distinct.  Classical CD11c+ 
myeloid DCs have been shown to initiate T-cell responses to both viruses (7) and 
aeroallergens (8).  The rare plasmacytoid (p)DCs, characterized by high expression of 
CD123, are also important in anti-viral immunity through their ability to produce large 
amounts of IFN- (9) but with respect to allergens, this cell population has been associated 
with induction of tolerance (10-12). The distribution of DC subsets is therefore relevant to 
local immune functions. This notion in underscored by the fact  that in children with a 
family history of atopy,  lower numbers of circulating pDCs was associated with more 
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frequent and more severe respiratory tract infections, wheezing and a diagnosis of asthma 
(13).  
An apparent difference between the airway immune system in infants compared with 
adults is the presence of bronchus-associated lymphoid tissue (BALT) (14; 15). BALT is 
part of the mucosa-associated lymphoid tissue and is defined as organized lymphoid 
aggregates within the bronchial mucosa in contact with the surface epithelium (15).  In 
mice, it has been shown that adaptive immune responses against influenza virus could be 
initiated in inducible BALT (16), but little is known about the function of these lymphoid 
structures in humans. BALT is not regularly found in fetuses, as opposed to the constitutive 
Peyer’s patches of the intestine, but is probably induced by antigen stimulation after birth 
(17). BALT in adults have primarily been associated with various diseases (15), but we and 
others have shown that they often are present in the bronchial mucosa during childhood (15; 
17; 18). To understand how adaptive response mechanisms operate in the airways of 
children both the function of AMDC subsets as well as the participation of BALT should be 
taken into account. 
We have recently characterized the distribution of immune cells in a biopsy material 
from bronchial mucosa of infants less than 2 years of age suffering from respiratory 
symptoms (18). We found that there was a tight network of antigen presenting cells (APCs) 
at the mucosal surface and that BALT was present in more than half of the samples. 
However, for obvious ethical reasons we were not able to obtain biopsies from normal 
individuals. To characterize the organization of the bronchial immune system at baseline we 
have performed a detailed characterization of the distribution and functional phenotype of 
APCs and the occurrence of BALT in the bronchial mucosa of children who died from non-
infectious causes and without any history or recent or chronic signs of airway disease. 
 
 
MATERIALS AND METHODS 
Subjects
Specimens from nine children aged 1.9 – 15.4 years (median 8.5) who died from traumatic 
causes and with no evidence of respiratory disease upon autopsy were examined. Oedema 
and hemorrhage were seen at the autopsies by the coronary in most of the samples due to the 
mechanism of death. None of the individuals had signs of atopic eczema. Samples were 
taken from the lower trachea or the main bronchi close to the carina. In two specimens, the 
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epithelium was absent. In one specimen the epithelium could only be evaluated in some 
sections, whereas in the remaining six, the quality of the epithelium was satisfactory.  
Immunohistochemistry
Specimens were formalin-fixed and paraffin-embedded. Sections cut at 4μm were examined 
by immunohistochemistry. For optimal staining results heat-induced epitope retrieval was 
performed by boiling the sections in a microwave oven for 20 min in citrate buffer (pH 6.0). 
Immunoenzyme staining on dewaxed tissue sections was performed in a Ventana 
NexEs IHC instrument (Tucson, AZ) with the standardized iView DAB or enhanced V-Red 
(alkaline phosphatase) detection kits as recommended by the manufacturer. The primary 
monoclonal antibodies (mAbs) were directed against human HLA-DR (clone TAL.1B5, 
IgG1, DakoCytomation, Glostrup, Denmark), CD68 (clone PG-M1, IgG3, 
DakoCytomation), CD11c (clone 5D11, IgG2a, Novocastra Lab. Ltd., Newcastle Upon 
Tyne, UK), CD1a (clone MTB1, IgG1, Novocastra), CD123 (a  mixture of clone 7G3, 
IgG2a, and clone 9F5, IgG1, BD Pharmingen, San Diego, CA), CD45RA (clone L48, BD 
Immunocytometry Syst., San Jose, CA) and CD20 (clone L26, IgG2a, DakoCytomation). A 
polyclonal rabbit anti-human CD3 (dilution 1/50; DakoCytomation) was additionally 
applied. 
Stained tissue sections were examined blindly by the same investigator (IH) at x 400 
magnification. The epithelium was missing in 2 individuals, and of very poor quality in one, 
thus epithelial counts could not be performed in all sections. The cell density in the 
epithelium was recorded as the total number of positive cell profiles per basement 
membrane length unit (1 mm), whereas the cell number in lamina propria was recorded as 
positive cell profiles per square millimeter. The total number of positive mucosal cells was 
recorded per basement membrane length unit by adding the intraepithelial counts and the 
lamina propria counts to a depth of the grid. On average, 50 visual fields were counted in 
each specimen. The mucosal areas containing lymphoid aggregates (see Results section) 
were omitted from the cell enumeration.  
Staining for the nuclear antigens FOXP3 and Ki67 with antibodies that normally 
work well on paraffin-sections were unsuccessful, probably due to post-mortem degradation 
of nuclear proteins.  
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RESULTS
Histologial evaluation 
H+E staining showed horizontally cut sections through the whole bronchial wall including 
parabronchial lymph nodes. The morphology in most specimens was very good with a well 
preserved surface epithelium in 7 out of 9 samples. In some sections the epithelium was 
partly detached from the underlying lamina propria. There was no accumulation of 
neutrophils or eosinophils or other signs of ongoing inflammation. In nearly all sections 
small cell aggregates in contact with the surface epithelium were observed indicative of 
isolated lymphoid follicles (ILFs; see below).  
 
BALT was found in all subjects 
To characterize the putative ILFs further we performed immunostaining experiments 
applying a range of mAbs to identify subsets of immune cells (Figure 1). All ILFs contained 
high numbers of HLA-DR+ APCs. (Figure 1A and B). The aggregates were also 
characterized by accumulation of CD3+ T cells and CD20+ B cells (Figure 1C and D). Most 
T cells were of the naïve phenotype judged by the dense population of CD45RA+ cells 
(Figure 1E and F). CD11c+ but not CD68+ cells accumulated in ILF (Figure 1G and not 
shown). Moreover, small numbers CD123+ pDCs were observed (Figure 1H) and some 
vessels expressed MECA-79 demonstrating that they were high endothelial venules (HEVs) 
(Figure 1I). Together, these structures could clearly be defined as BALT.  
The numbers of ILFs were counted in sections stained for CD3/CD20 and CD45RA 
which clearly delineated these structures (Figures 1C-F). Sections from all individuals 
contained ILFs with a median of 4 per section (range 1 to 11). The density of ILFs was 
determined by dividing the number with the bronchial circumference (Figure 2). With an 
estimated median ILF diameter of 200 μm, we calculated that the density of ILFs was 
approximately 60 per square cm of airway mucosa. This shows that BALT is a prominent 
feature of central airway mucosa in children from 1-15 years of age. 
 
Immune cell populations outside organized lymphoid tissue 
Apart from ILFs, HLA-DR+ cells were evenly distributed both within and beneath the 
surface epithelium constituting a dense network of large cells with variable morphology. 
Within the epithelium a median number of 34 HLA-DR+ cells per mm basement membrane 
(range 14 – 56) (Figure 3A), whereas in the lamina propria 342 HLA-DR+ cells per mm2 
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(range 172 – 424) (Figure 3B) were enumerated. Interestingly, intraepithelial HLA-DR+ 
cells frequently extended cell projections through the epithelium into the luminal side 
(Figure 4A).  
To further characterize the APC populations we determined the number of CD68+ 
macrophages and CD11c+ putative DCs (Figures 4B and C). The number of CD68+ and 
CD11c+ cells were quite similar both in the epithelium and in the lamina propria and the 
sum of these cell populations was close to 100 % of all HLA-DR+ cells in lamina propria 
and 60-70% of all HLA-DR+ cells in the epithelial compartment (Figure 3A and B). 
Additional co-staining experiments showed that there was only 10-20 % overlap between 
the two markers (Figure 4C), indicating that the mucosal APC populations were mainly 
made up of CD68+ macrophages and CD11c+ DCs.  We and others have found that some 
AMDCs express CD1a, a marker used to identify epidermal Langerhans cells. Only low 
densities of CD1a+ cells were found both in the epithelium (median 0.07, range 0 – 1) 
(Figure 3A) and in lamina propria (median 0.0, range 0.0 – 6) (Figure 3B). pDCs were also 
found scattered in the lamina propria (median 7, range 2 – 24) and within the epithelium in 
some specimens (median 0.25, range 0 – 2) (Figure 3A and  B) 
   
T- and B cells outside organized lymphoid tissue 
CD3+ T cells were observed evenly distributed throughout the surface epithelium and 
lamina propria (Figure 5). However, the CD45RA+ phenotype was restricted to ILFs 
demonstrating that mucosal T cells were CD45RA- memory/effector cells. Only very few 
CD20+ B cells were found outside ILFs (Figure 5).  
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DISCUSSION 
Here we show that DCs, macrophages and T cells constituted a dense network of immune 
cells both beneath and within the surface epithelium in the normal bronchial mucosa of 
children between 1 and 16 years of age. Importantly, organized lymphoid tissue in close 
proximity to the surface epithelium, identified as BALT, also appeared to be a normal 
constituent of the local immune system. This shows that the density and composition of 
immune cells in the lamina propria of the bronchial mucosa in children are very similar to 
adults. However, in addition the mucosa in children also contains densely dispersed 
inductive sites which most likely contribute significantly in generating immune responses to 
inhaled antigens. 
We have previously determined the density of APC subsets in bronchial biopsies 
from 45 infants less than two years of age with respiratory symptoms (18). Both the 
anatomical distribution and density of HLA-DR+ cells and CD68+ cells were similar to what 
were reported here. Since there were no signs of inflammation, assessed by infiltration of 
granulocytes, in any of these studies, the similar results suggest that they represent the 
homeostatic distribution of APCs in children. Here we also showed that the vast majority of 
CD11c+ cells were negative for CD68. This finding strengthens the notion that these cells 
indeed are mucosal myeloid DCs. The individuals in the present study were older than in 
our previous biopsy study. In the post mortem material there was no correlation between 
cell numbers and age, like we found in infants from 0-2 years, suggesting that the number of 
myeloid DCs and macrophages reach steady-state levels at approximately two years of age.   
DCs in the gut have been shown to express tight junction proteins and sample 
bacterial antigen from the gut lumen in response to inflammatory stimuli (19). Our 
observation that “snorkeling DCs” may be found even in the absence of inflammatory 
conditions, suggests that this is a phenomenon taking place under homeostatic conditions, 
and possibly a means by which DCs sample innocuous material for the induction of 
tolerance (1). 
ILFs as part of BALT were observed in mucosal samples from all individuals. They 
contained naïve T cells, B cells, both CD11c+ myeloid DCs and pDCs, and in some follicles 
HEVs and follicular DCs were also observed. We estimated the density of ILFs to 
approximately 60 per square cm demonstrating that these structures are an integral part of 
the mucosal immune system. In the previous biopsy study (18) we identified ILFs in 
approximately 50 % of the biopsy samples. Because biopsy specimens from the bronchial 
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mucosa of infants were very small we would not expect to find ILFs in more than half of the 
cases with a density of 60/cm2.  Therefore, it seems that BALT develops within months after 
birth and is an essential component of the mucosal immune system in the bronchi during 
childhood.  Tschernig et al. found BALT in children but only in a fraction (44 %) of those 
who died from trauma (20). The difference between the latter report and ours could at least 
in part be due to the criteria used to define these structures. We identified ILFs as aggregates 
of naïve T cell and B cells that were in contact with the overlying surface epithelium and 
showed that these structures also contained DCs and HEVs. Tschernig et al. based their 
identification of BALT on routinely stained sections. In our experience, identification of 
BALT by immunostaining is a much more sensitive technique. Most functional 
immunological studies have emphasized the importance of DCs migrating to the draining 
lymph nodes to prime the adaptive immune system. Inducible BALT in mice was recently 
found to be dependent on CD11c+ DCs for maintenance (21). Here we show that naïve T 
and B cells are found together with DCs as organized lymphoid tissue beneath and with the 
surface epithelium in high densities. This may suggest that the immune response to 
aereoantigens in infants may be initiated to a large extent locally without the participation of 
the regional lymph nodes. Studies in experimental mice have shown that induced BALT 
generated strong primary T- and B-cell immune responses when infected with virus (16; 
21). These structures should therefore be taken into account when studying the airway 
immune system in infants and its importance for health and disease.  
pDCs have been shown to be vital inducers of tolerance to airway allergens in mouse 
models (12) and levels of pDCs during infancy were inversely correlated with symptoms of 
lower respiratory tract infections, parent-reported wheezing, and the cumulative rate of 
physician-diagnosed asthma up to age 5 years (13). Here we confirm our previous findings 
that in airway mucosa of children pDCs are primarily located within BALT, but in addition 
we show that they are also found scattered in the LP and even within the epithelium, 
suggesting that they may play a role in mucosal homeostasis. 
Studies have shown that the immune system in children is immature which explain 
the high degree of viral infections and allergic sensitization (3). To understand the function 
of the immune system all structural features must be taken into account. This paper 
contributes to the understanding of the mucosal immune system in early life. APCs are 
strategically positioned within the epithelium and actively penetrate the epithelial barrier 
with cellular extensions making these cells very suitable for sensing the luminal content of 
antigens. Moreover, aeroantigens may be handled locally by the high number of BALT, 
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which includes mDCs and pDCs, cells essential in modulating adaptive immune responses. 
These aspects must be taken into account during mucosal vaccine development.
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FIGURE LEGENDS 
Figure 1. The bronchial muocosa of children harbors distinct subepithelial cellular 
aggregates in which APCs, naïve T cells and B cells accumulate. Immunoenzyme 
staining for HLA-DR (A and B), CD3 and CD20 (B and C), CD45RA (E and F), CD11c 
(G), CD123 (H) and MECA (I) of sections from the bronchial wall. HLA-DR+ APCs are 
diffusely distributed throughout the lamina propria and the epithelium and additionally 
accumulate in distinct subepithelial aggregates (A and B). These aggregates contain T and B 
cells, as determined by the expression of CD3 and CD20 (C and D). CD45RA+ naïve T cells 
accumulate in these aggregates but are not found elsewhere in the mucosa (E and F). 
CD11c+ mDCs are found at high densities in the aggregates (G).  CD123+ pDCs were rarer 
but found at highest densities within lymphoid aggregates (H). Some lymphoid aggregates 
contained MECA+ cells, a marker of high endothelial venules (I). Magnifications: (C and 
E): x40 (A): x100, (D and I): x200, (B and H): x400, (F and G): x600. 
 
Figure 2. BALT was found in all individuals studied. The total numbers of isolated 
lymphoid follicles (ILFs) were counted in sections stained for CD45RA and CD3/CD20 and 
given as numbers of ILFs per mm basement membrane 
Data are shown with median and interquartile range. 
 
Figure 3. Density of APC subsets in epithelium and in lamina propria. The density of 
HLA-DR+, CD68+, CD11c+, CD1a+ and CD123+ cells in the epithelium (A) and in lamina 
propria (B) were calculated per millimeter basement membrane and per mm2, respectively. 
 
Figure 4. HLA-DR+ and CD11c+ cells in the epithelium extend dendritic projections 
reaching the luminal surface. Immunoenzyme staining for HLA-DR (A) CD11c (B) and 
double staining with CD11c and CD68 (C) of sections from bronchial wall. HLA-DR+ cells 
were seen with extensions reaching the luminal surface (A). Intraepithelial CD11c+ cells 
also had long extensions, but were not found to reach the surface (B). Double staining with 
macrophage marker CD68 and DC marker CD11c showed rare double positive cells, 
approximately 10 % of total CD11c+ numbers. Magnification: all panels x600.
Figure 5. T cells were found throughout the mucosa whereas only very few B cells were 
observed outside ILFs. Immunoenzyme staining for T cells (CD3) and B cells (CD20) of 
section from bronchial wall. Magnification: x600.  
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ABSTRACT 
Background: Sun exposure is a well-described treatment modality for psoriasis and 
UV-radiation modifies several aspects of the immune system.  
Objectives:  We wanted to characterise early sun-induced immunological changes 
both locally and systemically in psoriatic patients.  
Methods: 20 patients with moderate to severe psoriasis were subjected to controlled 
sun exposure on Gran Canaria. PASI-scores were evaluated clinically. Skin biopsies 
were obtained from lesional and non-lesional skin in ten patients at baseline and day 
16 of sun exposure and from five additionally at day 2. Specimens were examined by 
immunohistochemistry and PCR. Blood samples were obtained from all patients at the 
same time points and examined for T-cell subsets and cytokine production.  
Results: Significant clinical improvement was achieved during the study period. After 
only one day intraepithelial T cells were markedly decreased and after 16 days CD4+ 
and CD8+ T cells in lesional skin were significantly reduced in both epidermis and 
dermis. In contrast, FOXP3+ T cells remained unchanged. We found evidence of 
reduced mRNA expression of interleukin (IL)-23 and IL-17 in lesional skin. In 
peripheral blood, skin homing cutaneous lymphocyte-associated antigen (CLA)+ T 
cells decreased significantly after only one day in the sun and in vitro-stimulated 
peripheral blood mononuclear cells demonstrated reduced capacity to release pro-
inflammatory cytokines after 16 days.  
Conclusions: Our data show that clinical improvement of psoriasis following sun 
exposure is preceded by rapid reduction in inflammatory parameters locally and 
systemically, strongly suggesting that immune modulation mediated the observed 
effect. We cannot completely rule out that other mechanisms, such as stress reduction, 
are of any importance. However, it has been extensively documented that UV 
exposure is a potent inducer of immunosuppression and we therefore find it most 
likely that the observed effect was primarily due to sun exposure. 
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INTRODUCTION
Psoriasis is one of the most prevalent autoimmune skin diseases affecting 2-3% of 
caucasians 1. It is a chronic disorder with serious medical consequences and impairment of 
quality of life for patients 2. Psoriatic skin lesions are sharply demarcated, erythematous, 
raised, scaling plaques of varying extent but nails, joints and other organs can also be 
affected 1. The primary event is widely held to be immunological with hyperstimulatory 
antigen presenting cells (APCs) and autoreactive T cells in the dermis initiating the 
pathogenic process 3;4. The developing cytokine network attracts additional immune cells 
and perpetuates the inflammatory cascade, inducing the pathological findings characteristic 
of the disease 5.  
Tumor necrosis factor (TNF)- has been shown to be important in driving immune 
pathology in psoriasis and the use of anti-TNF-agents is now a well established treatment 
modality for this disease 6. However, more recently, the focus of attention has shifted to 
interleukin (IL)-17-producing T helper cells (Th17), which have been found to be central to 
the pathogenesis of this disorder 7-10. IL-23, produced by dendritic cells (DCs) and 
overexpressed in psoriatic lesions 11, stimulates survival and proliferation of Th17 cells and 
thus may serve as a key master cytokine regulator for this disease 12. The therapeutic 
efficacy of an anti-IL-12/IL-23 antibody on moderate-to-severe plaque psoriasis as well as 
on psoriasis arthritis was recently demonstrated 13;14.  
While therapeutic monoclonal antibodies are effective, their use is expensive and 
long-term data on safety are still lacking 15. Natural sun, which has been used for decades in 
the treatment of psoriasis, has a potent clinical effect potentially involving 
immunoregulatory mechanisms 16-18. Immunosuppression following UVB exposure has 
been described locally in the skin and in the systemic compartment 19. Induction of 
regulatory T cells (Treg) has been suggested to be one mechanism mediating the clinical 
effect of UVB treatment 20;21. Vitamin D, produced locally in the skin upon sun exposure, 
has also been shown to contribute to the immunological changes seen in the skin upon UVB 
exposure 21;22. However, most of these studies are performed in mouse models and human 
data are scarce. On this background, we wanted to study the early immunomodulatory 
effects of sun exposure in psoriatic patients both in situ, in non-lesional and lesional skin, as 
well as in the systemic compartment.  
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MATERIALS AND METHODS 
Subjects
Heliotherapy is a well established therapeutic modality for patients with psoriasis in 
Scandinavian countries and approximately 500 Norwegian psoriatic patients are selected for 
heliotherapy annually.
20 patients (median age 48 years, range 24-65, 6 females) were enrolled in the study 
and transported from Norway to Gran Canaria, Spain, in the month of March. The patients 
were evaluated by the same dermatologist for the Psoriasis Area and Severity Index (PASI) 
23 before and after sun treatment. All patients had moderate to severe plaque psoriasis, i.e. 
mean/median PASI before climatotherapy of 9.8/8.7, range 3.8-18.8. All patients had 
stopped using any psoriasis medication at least 4 weeks prior to this study. Two of the 
patients had skin type II and 18 had skin type III according to the Fitzpatrick classification 
24. Patients eligible to receive climate therapy are preferred to have darker skin types in 
order to avoid potentially adverse effects of sun exposure. UV-doses were measured and 
details were described by Nilsen et al. 25.
The study followed the protocols of the Helsinki declaration and was approved by 
the Regional Committee of Medical Ethics. All patients gave their written, informed 
consent. 
 
Skin biopsies and blood samples 
4 mm punch biopsy samples were collected from lesional and non-lesional skin in 10 
randomly selected patients. The samples from each individual patient were obtained within 
the same body area on all days but in sufficient distance to avoid a reactive inflammation 
from prior biopsy sampling. Specimens from 5 patients at obtained baseline and at day 16 
were formalin-fixed and paraffin-embedded, whereas samples from another 5 patients 
obtained at baseline and days 2 and 16 were snap frozen in liquid nitrogen and stored at -80 
C until sectioning.  
Venous blood samples were collected from all 20 patients on days 0, 2 and 16. 
Mononuclear cells were isolated immediately for further investigations (see below).  
Immunohistochemistry
Formalin-fixed and paraffin-embedded biopsies were cut at 4 m. Immunoenzyme staining 
for CD1a (mouse IgG1, clone MTB1, Novocastra, Newcastle, UK) and CD8 (mouse IgG1, 
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clone C8/144B, DakoCytomation, Glostrup, Denmark) on dewaxed tissue sections was 
performed in a Ventana NexEs IHC instrument (Tucson, AZ) with the standardized iView 
DAB detection kits as recommended by the manufacturer. Two-colour immunofluorescence 
staining of formalin-fixed specimens was performed combining rabbit anti-CD3 (clone SP7, 
Thermo Fisher Scientific, Fremont, CA), and mouse anti-CD4 (IgG1, clone 1F6, 
Novocastra) or rabbit polyclonal anti-CD3 (DakoCytomation) and mouse anti-FOXP3 
(IgG1, clone 259D/7C, BD Pharmingen, San Diego, CA). The following secondary 
antibodies were used: Alexa 555 goat anti-rabbit, Alexa 488 goat anti-mouse, Alexa Fluor 
488 goat anti-rabbit IgG (all from Molecular Probes, Eugene, OR) and Cy3-conjugated goat 
anti-mouse IgG (Jackson ImmunoResearch, West Grove, PA).  
Cryosections were cut 4 m thick and fixed in acetone prior to staining. Two-colour 
immunofluorescence staining was performed combining rabbit polyclonal anti-CD3 
(DakoCytomation) with mouse anti-CD4 (IgG1, clone SK3, BD Pharmingen), mouse anti-
CD8 (IgG1, clone SK1, BD Pharmingen) or mouse anti-FOXP3 (clone 259D/7C, BD 
Pharmingen). Staining for LCs was performed with anti-CD1a (clone NA1/34, 
DakoCytomation). The following fluorescence-labelled secondary antibodies were used: 
Alexa 488 goat anti-rabbit IgG (Molecular Probes) and Cy3 goat anti-mouse IgG (Jackson 
Immunoresearch).  
Stained sections were examined by light or fluorescence microscopy at x 400 
magnification by the same investigator (IH). Cell numbers were recorded using an ocular 
grid (250μm x 250μm), counting positive cell profiles in epidermis and in the papillary and 
reticular dermis, to a depth of 250 μm. For the grossly thickened epidermis of psoriatic 
lesions, cell numbers per square millimetre rather than per millimetre of surface epidermis 
will reflect the cell density more accurately. Data for both dermal and epidermal cell counts 
are given as cells numbers per square millimetre, in both lesional and non-lesional skin, in 
order to make comparisons.  
mRNA from skin biopsies
RNA was isolated from 5 x 14 μm cryosections collected in 1.5 ml eppendorf tube 
containing 500 l TRI Reagent Solution (Applied Biosystems; Foster City, CA) and 1 g 
used for a 20-l cDNA synthesis reaction with SuperScript III (Invitrogen, Carlsbad, CA) 
and 20 pmol oligo dT. Primers for real-time PCR were designed with primer 3 software 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). Sequences are given in Table 
1. 1 l cDNA was used as template for real-time PCR in Stratagene MX3000P with 0.125 
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U/l HotStar Taq polymerase (Qiagen, Hilden, Germany), EvaGreen® (Biotium; 0.5x 
recommended amount) and MgCl2 concentration as indicated in Table 1. PCR conditions 
included 15 min 95ºC followed by cycling conditions as follows: 95ºC, 30 sek; annealing 
60ºC 30 sek; 72 ºC 30 sek. Each target mRNA was quantified by Ct (threshold crossing 
point) values using a cDNA pooled from several IBD patients to generate a standard curve 
and related to the GAPDH mRNA level. Melting curves were monitored for specificity of 
PCR products.
Flow cytometric analysis of peripheral blood T cells
EDTA-whole blood was incubated with monoclonal antibodies in the following 
combinations: CD3 peridinin chlorophyll protein (PerCP)/CD4 phycoerythrin (PE)/CLA-
fluorescein isothiocyanate (FITC)/CD45 allophycocyanin (APC) and CD3-PerCP/CD8-
PE/CLA-FITC/CD45-APC, and with isotypic-matched irrelevant antibodies (all from BD 
Biosciences, San Jose, CA). After 20 minutes at room temperature in the dark, erythrocyte 
lysis was performed. Samples were then washed in PBS and cells were examined by flow 
cytometry (FACSCalibur®, BD Biosciences). At least 10.000 lymphocytes were gated by 
forward and side scatter and CD45 expression. The collected data were analyzed using 
CellQuest Pro software (Apple computer, Inc; Cupertino, CA).  
 
Release of cytokines from PBMCs 
PBMCs, obtained from heparinized blood by isopaque-Ficoll (Lymphoprep, Nycomed 
Pharma, Oslo, Norway) gradient centrifugation, were incubated in flat-bottomed 96-well 
trays (Costar, Corning Inc., Corning, NY; 2x106 cells/mL; 100 μL/well) in medium alone 
(RPMI-1640 containing 2 mM L-glutamine Sigma Chemical Co., St. Louis, MO, 
supplemented with 100 U/mL penicillin and 5% fetal calf serum), or with 
phytohaemagglutinin (PHA; Murex, Dartford, UK; final concentration 5 μg/mL). Cell-free 
supernatants were harvested after culturing for 24 hours and stored at -80oC until analysis. 
Cytokine measurements 
Cytokine levels in cell-free supernatants were analysed using a multiplex cytokine assay 
(Bio-Plex Human Cytokine 8-Plex Panel, Bio-Rad Laboratories Inc., Hercules, CA), 
according to the instructions from the manufacturer. 
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Statistical analysis 
Paired non-parametric tests Wilcoxon signed rank test was used to examine differences 
within the same individuals over time. Because biopsy specimens from day 2 were available 
from only 5 individuals, these in situ-data were omitted from the statistical analyses. P-
values <0.05 were interpreted as significant
 
 
RESULTS
Clinical score  
All patients experienced clinical improvement, and the mean reduction of Psoriasis Area 
and Severity Index (PASI) scores was 72.8% after 16 days of climatotherapy (Fig. 1a).  
 
16 days of sun exposure induced reduction in lesional epidermal thickness  
Biopsies obtained from lesional and non-lesional skin at baseline at day 2 and 16 of sun 
exposure were examined by immunohistochemistry. At baseline, non-lesional skin was 
normal histologically, whereas lesional skin showed severe pathology with parakeratosis, 
thickened epithelium, elongated papillae and inflammatory infiltrates (Fig. 2a-b). No 
changes in epidermal thickness were seen after sun exposure in non-lesional skin (Fig.1b). 
In lesional skin 16 days of sun exposure induced a significant reduction in epidermal 
thickness (Figs.1b and 2b-c).  
T cell populations in the epidermal and dermal compartments are rapidly reduced by 
sun exposure 
As T cells are central in driving psoriasis pathology 3;4, we wanted to examine the early 
impact of sun exposure on CD4+, CD8+ and regulatory T-cell populations in situ. Samples 
(frozen or formalin-fixed) from 10 patients were examined by immunohistochemistry and 
positive stained cells were enumerated. Cell densities are presented as cell numbers per mm2 
for the epidermal (Fig. 3) and dermal (Fig. 4) compartments separately.  
 
Epidermal compartment 
Sections from non-lesional skin contained low numbers of epidermal T cells (Figs. 2, 
left panels and 3a, c and e). CD4+ T cells infiltrating the epidermis were moderately elevated 
in lesional skin, (P=0.0005, Figs. 2e and 3b), whereas epidermal CD8+ T cells were 
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dramatically increased (P<0.0001, Figs. 2h and 3d). Sun exposure resulted in significant 
reductions in epidermal CD4+ T cells in both non-lesional and lesional skin (Figs. 2f and 3a-
b). Epidermal CD8+ T cells in non-lesional skin were unaffected (Fig. 3c), whereas in 
lesional skin, they were reduced to non-lesional levels at day 16 (Figs. 2h-i and 3d). Both 
CD4+ and CD8+ T cells were markedly reduced in the epidermis already at day 2, although 
these differences could not be tested statistically (Fig. 3b and d). FOXP3+ T cells (putative 
Tregs) were increased in lesional epidermis compared with non-lesional (P=0.033). Non-
lesional epidermal FOXP3+ T cells were unaffected by sun exposure (Fig. 3e), whereas in 
lesional skin, they were significantly reduced at day 16 (Figs. 2k-l and 3f). 
 
Dermal compartment
CD4+ and CD8+ T cells were significantly increased at in lesional dermis at baseline 
compared with non-lesional dermis (P<0.0001 for both subsets, Fig. 4a-d). In non-lesional 
dermis, no significant changes in CD4+ or CD8+ T cell numbers were observed after sun 
exposure (Fig. 4a and c). In lesional dermis, however, both T-cell subsets were significantly 
reduced on day 16 of sun exposure (Fig. 4b and d). 
Dermal FOXP3+ T cells were also increased in lesional skin (P=0.002, Fig. 4e-f). In 
lesional dermis, the number of FOXP3+ T cells remained unchanged after sun exposure 
(Fig. 4f), suggesting a relative increase in Tregs, although the percentage of FOXP3+ CD4+ 
T cells did not reach statistical significance (data not shown).  
For all T cell subsets studied, a redistribution of infiltrates could be observed after 
sun exposure, with the most dramatic reduction in cell numbers in the epidermis and 
papillary dermis, whereas infiltrates in the reticular dermis persisted (Fig.2). 
 
The density of Langerhans cells was decreased in lesional epidermis  
In contrast to the other cell populations studied, the densities of Langerhans cells (LCs), 
defined as epidermal CD1a+ cells per mm2, were profoundly reduced in lesional skin at 
baseline, compared with non-lesional epidermis (P<0.0001, Figs. 3g-h and 5a and c). In non-
lesional epidermis LCs, as expected, were dramatically reduced upon sun exposure (Figs. 3g 
and 5a-b). In lesional epidermis, there was a slight but significant reduction in LC numbers 
after sun exposure (Figs. 3h and 5c-d). There was no difference in numbers of dermal CD1a+ 
cells between non-lesional and lesional skin at baseline. The density of dermal CD1a+ cells 
remained unchanged in non-lesional dermis after sun exposure, whereas in lesional dermis a 
significant reduction was observed (Figs. 4g-h and 5a-d).  
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Cytokine gene expression in lesional skin 
In order to investigate whether sun induced reduction in T cell numbers was associated with 
reduction in cytokine gene expression mRNA was isolated from the same frozen biopsies 
that were examined by immunohistochemistry. In samples from non-lesional skin, very low 
levels of cytokines were detected (data not shown). From lesional specimens, unfortunately, 
only samples from four individuals yielded results of satisfactory quality, so no statistics 
could be performed on these data. However, clear trends could be observed for some of the 
cytokines. Expression levels of TNF- was markedly reduced in 3 out of 4 individuals at 
day 2, whereas it was unchanged at day 16 (Fig. 6a). IL-12p40 (also part of IL-23) was 
reduced in 4 out of 4 individuals at day 16 (Fig. 6b). IL-23p19 and IL-17, showed markedly 
reduced expression levels in 3 out of 4 individuals on both day 2 and day 16 of sun exposure 
(Fig. 6c-d). In contrast, expression levels of the anti-inflammatory cytokine IL-10 was 
increased in 3 out of 4 individuals on day 16 (Fig. 6e), whereas transforming growth factor 
(TGF)- seemed unchanged (Fig. 6f). 
The frequency of CLA+T cells in peripheral blood was reduced already at day 2 of sun 
exposure
To study the impact of immune function in the systemic compartment, we next examined 
whether sun exposure affected circulating skin homing T cells, characterized by expression 
of the homing marker cutaneous lymphocyte antigen (CLA). PBMCs obtained from blood 
samples from all 20 patients at baseline, day 2 and day 16 of sun exposure, were examined 
by flow cytometry. Total numbers of CD3+ T cells, CD4+ T cells and CD8+ T cells were 
unaffected by sun exposure (data not shown). The frequencies of both CD4+ and CD8+ 
CLA+ T cells as a percentage of total T cells (not shown) as well as a percentage of CD4+ 
and CD8+ T cells (Fig. 7a-b) were significantly decreased already at day 2 and remained 
low at day 16 of sun exposure, demonstrating a selective reduction of CLA+ T cells in the 
peripheral blood.  
 
Release of cytokines from peripheral blood mononuclear cells (PBMCs) ex vivo
We next examined the release of cytokines from unstimulated and PHA-stimulated PBMCs 
obtained from all 20 patients at baseline, day 2 and day 16. Supernatants were removed after 
culturing cells for 24 hours. In supernatants from unstimulated cells, all cytokine 
concentrations were below detection limit (data not shown). There was no difference in 
cytokine secretion in PBMCs obtained after 2 days of sun exposure. After16 days, PBMCs 
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released significantly less interferon (IFN)-, IL-17, TNF- and IL-10 compared to baseline 
levels (Fig. 8a-d), whereas the reduction in IL-12p40 release was non-significant (Fig. 8e). 
 
 
DISCUSSION 
This study demonstrated that 16 days of natural sun exposure induced excellent clinical 
improvement in psoriatic patients. The clinical response was preceded by rapid 
immunological changes both in situ and systemically.  
Previous studies have demonstrated that UVB irradiation induces apoptosis of T 
cells but not CD1a+ cells in psoriatic lesions 26;27. The fact that the most pronounced 
depletion of both CD4+ and CD8+ T cells was seen in the epidermis and upper parts of the 
papillary dermis, strongly suggests that apoptosis could contribute to the massive reduction 
of T cells upon sun exposure in affected skin in our study population 27. In order to examine 
the specimens for evidence of apoptosis, we stained for cleaved caspase-3, but could not 
detect any positive signals, in spite of good results in positive control samples. We speculate 
that one explanation for this could be due to timing and that the product of apoptosis 
detected by this method may not be optimally expressed at the time points on which our 
biopsies were sampled. 
 Epidermal FOXP3+ cells were near depleted along with the two main cell subsets.  
In contrast, dermal FOXP3+ T cells remained unchanged after 16 days of sun exposure, 
suggesting that the induction of Tregs is one of the mechanisms mediating sun induced 
improvement in psoriasis. A possible explanation for the differential effect on FOXP3+ T-
cell numbers in the two compartments could be that the dermal cells are less susceptible to 
apoptosis and that newly recruited Tregs, reflecting a change in the local cytokine milieu, will 
be found in the dermis under such circumstances.  
Unfortunately, our mRNA data were of insufficient quality to enable us to draw 
conclusions, but they suggest that reductions in cell numbers are paralleled by reduction in 
pro-inflammatory cytokines. It has previously been shown that 3 weeks of UVB treatment 
reduced expression of IL-23p19 28 and that 8 weeks of cyclosporine treatment reduced IL-17 
expression in psoriatic skin 29. Together, these data are in line with recent reports 9;30;31 
demonstrating that Th17 cells are central in immunopathology of psoriasis and indicate that 
sun exposure may down-regulate the IL-23/IL-17-axis, potentially contributing to its 
beneficial effects in psoriatic patients. The increased IL-10 mRNA levels in lesional skin in 
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3 out of 4 individuals at day 16 also supports the concept of a change from an inflammatory 
into a more homeostatic environment upon sun exposure.   
We demonstrate for the first time that skin homing CLA+CD4+ and CLA+CD8+ T 
cells in peripheral blood decreases significantly in psoriatic patients after only one day of 
sun exposure. Previously, it has been shown that UVB exposure reduces total CLA+ T cells 
in the blood of psoriatic patients after one week 32. The rapid decrease of CLA+ T cells in 
peripheral blood could be caused by an increased migration to both lesional and non-
lesional skin. However, cell numbers in non-lesional skin were unchanged whereas they 
were markedly reduced in lesional skin after sun exposure. As CLA+ T cells preferentially 
circulate to the skin, they would be susceptible to apoptosis and thus peripheral numbers 
would decrease. Whether UV-irradiation could have a direct down-regulatory effect on 
CLA has not been established. The attenuated capacity of in vitro-cultured PBMCs to 
produce cytokines after sun exposure, suggests that sun exposure also induced functional 
changes in the systemic compartment. This is in line with previous studies on the 
immunomodulatory effects of UV radiation and could be mediated by several different 
mechanisms 33;34.  
LCs have previously been found in decreased densities in psoriatic lesions 35. We 
confirm this finding and our data also support previous reports of LCs having impaired 
migratory function in psoriatic patients 36.  LCs normally leave the epidermis and migrate to 
regional lymph nodes upon UV-exposure 37. However, we found that LCs in lesional 
epidermis, in contrast to CD4+ and CD8+ and FOXP3+ lymphocyte populations, were only 
slightly reduced in numbers upon sun exposure, suggesting impaired migratory function. 
LCs in non-lesional epidermis, as expected, were dramatically reduced after sun exposure, 
suggesting that this impaired migration is not a primary defect in psoriasis.  
Warm climate and bathing in combination with sun exposure might reduce stress and 
thereby indirectly improve the psoriasis lesions in addition to the UV-induced effects. 
However, there is a large body of evidence to suggest that UV exposure under experimental 
conditions have a very strong immunosuppressive effect, which is compatible with the idea 
that reduction in pathogenic T cells is mainly due to sun treatment. 
 In conclusion, the present study shows that exposure to natural sun induces excellent 
clinical improvement within 16 days associated with a rapid reduction of skin homing T 
cells from the peripheral blood and of T cells from lesional skin with a relative increase in 
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Tregs. The concomitant change in the systemic cytokine profile favoring an 
immunosuppressive environment, may contribute to the resolution of inflammation. 
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 mRNA target 
(gene name) Primer sequence (5’ to 3’, forward primer written on top) 
 
Product  
size (bp) 
 
MgCl2 
conc. (mM) 
 
hIL10 
 
 
hIL12B (p40) 
 
 
hIL17A 
 
 
hIL23A (p19) 
 
 
hTGFB1 
 
 
hTNF 
 
 
 
hGAPDH 
TTACCTGGAGGAGGTGATGC 
GGCCTTGCTCTTGTTTTCAC 
 
TACTCCACATTCCTACTTCT 
CGTGAAGACTCTATCTTTCT 
 
AGGCACAAACTCATCCATCC 
GCTCAGCAGCAGTAGCAGTG 
 
GACACATGGATCTAAGAGAA 
AGCAGAACTGACTGTTGTC 
 
GTGGAAACCCACAACGAAAT 
CGGAGCTCTGATGTGTTGAA 
 
AGCCCATGTTGTAGCAAACC 
TGAGGTACAGGCCCTCTGAT 
 
TGTTCGACAGTCAGCCGCATCTTCT 
TGATGGCAACAATATCCACTTTACCAGAGTT 
 
148 
 
 
 85 
 
 
 91 
 
 
114 
 
 
 83 
 
 
134 
 
 
161 
 
2.0 
 
 
4.0 
 
 
2.5 
 
 
3.0 
 
 
2.5 
 
 
2.5 
 
 
2.0 
Table 1   Primer sequences used for RT- PCR analyses 
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FIGURE LEGENDS 
Figure 1. PASI-scoring and reduction in epidermal thickening. Twenty patients received 
controlled natural sun exposure for 16 days. All patients showed clinical improvement and 
PASI-scoring showed a significant reduction at day 16 (a). Epidermal thickness in 
specimens was unchanged in non-lesional skin after 16 days of sun exposure (n=10), 
whereas in lesional skin epidermal thickness was significantly reduced (n=10) (b). 
 
 
Figure 2.  Histology and immunohistochemistry of cryosections (a-i) and formalin fixed 
sections (j-m). Sections shown are from non-lesional skin at baseline (left panels), from 
lesional skin at baseline (middle panels) and after 16 days of sun exposure (right panels). 
Hematoxyline-Eosin-stained sections showed a reduction in epidermal thickness and of 
inflammatory cell infiltrates (a-c). In situ phenotypic characterization of T cell populations 
was performed by paired immunofluorescence staining with CD3 (Alexa 488, green) and 
CD4 (Cy3, red) (d-f), CD8 (Cy3, red) (g-i), and FOXP3 (Cy3, red) (j-m). Double positive 
cells appear yellow. The white dotted line denotes the dermo-epidermal junction. Note the 
reduction in T cells populations in lesional skin at day 16, especially in epidermal and 
papillary dermal compartments. Images (a-l) are at 200x magnification. Panel (m) shows 
CD3+FOXP3+ cells in lesional dermis at 600x magnification. The anti-FOXP3-antibody 
showed unspecific staining of the upper epidermis in all specimens obtained after sun 
exposure (l). 
Figure 3. Numbers of immunostained cells expressed per mm2 for the epidermal 
compartment in non-lesional (left panels) and lesional skin (right panels) at baseline and on 
days 2 and 16 of sun exposure (n=10). Numbers for the following cell populations are 
shown: CD3+CD4+ cells (a and b), CD3+CD8+ cells (c and d), CD3+FOXP3+ cells (e and f) 
and CD1a+ cells (g and h).  
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Figure 4. Numbers of dermal immunostained cells expressed per mm2 in non-lesional (left 
panels) and lesional skin (right panels) at baseline and on days 2 and 16 of sun exposure 
(n=10). Numbers for the following cell populations are shown: CD3+CD4+ cells (a and b), 
CD3+CD8+ cells (c and d), CD3+FOXP3+ cells (e and f) and CD1a+ cells (g and h).  
 
 
Figure 5. CD1a+ Langerhans cells in non-lesional (upper panels) and lesional skin (lower 
panels) at baseline (left panels) and at day 16 of sun exposure (right panels). The density of 
epidermal CD1a+ LCs was reduced in lesional skin compared with non-lesional skin (a and 
b). After sun exposure, LCs were dramatically reduced in non-lesional epidermis (c), 
whereas the reduction in lesional epidermis was significant but less pronounced (d). 
Figure 6.  Cytokine mRNA in frozen biopsy specimens obtained at baseline and on days 2 
and 16 after sun exposure. Unfortunately, only 4 specimens yielded qualitatively satisfying 
results, so no statistics could be performed. RT-PCR was performed to investigate 
expression levels of the following cytokines, TNF- (a), IL-12p40 (common subunit of IL-
12 and IL-23) (b), IL-23p19 (c), IL-17 (d), IL-10 (e) and TGF- (f). Expression levels are 
normalized to GAPDH. 
 
 
Figure 7.  CLA+ T lymphocyte subpopulations in peripheral blood at baseline and on days 2 
and 16 of sun exposure analysed by flow cytometry. The percentage of CD4+CLA+ cells of 
CD4+ T cells (a) and CD8+CLA+ cells of  CD8+ T cells (d) were significantly reduced. Data 
are mean±SEM of all 20 patients. ***, P<0.001, **, P<0.01 versus baseline.  
 
 
Figure 8. Cytokine release from PHA-stimulated PBMCs obtained at baseline and on days 
2 and 16 of sun exposure. The release of IFN- (a), IL-17 (b), TNF- (c), IL-10 (d) were all 
significantly reduced in PBMCs obtained at day 16. The reduction in the release of IL-
12p40 (common subunit of IL-12 and IL-23) (e) did not quite reach statistical significance. 
Data are mean±SEM of all 20 patients.  **, P<0.01; *, P<0.05; #, P=0.064 versus baseline. 
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ABSTRACT 
 
Interferon (IFN)- producing plasmacytoid dendritic cells (pDCs) and inflammatory 
CD11c+CD1c- myeloid DCs accumulate in the dermis of psoriatic lesions and are 
believed to play a central role in the pathogenesis of the disease. Here, we show that 16 
days of heliotherapy had excellent clinical effect on psoriatic patients that concurred with 
reduced numbers of pDCs and reduced expression of MxA, a surrogate marker for IFN-
, in lesional skin. A rapid reduction in CD11c+CD1c- myeloid DCs (mDCs) was also 
observed whereas the density of resident dermal CD11c+CD1c+ mDCs was unaffected. 
Sun exposure also led to reduced expression of the maturation marker DC-LAMP on 
mDCs. A significant decrease in lesional dermal macrophages was also observed.  In 
conclusion, we show that the clinical effect of sun exposure in psoriasis is strongly 
associated with rapid changes in dermal DC populations in lesional skin, which partly 
precede the clinical effect. These findings add further evidence to the notion that these 
cells are directly involved in the pathogenesis of the disease, and suggest that UV-
induced immunosuppression, at least in part, can be explained by its effect on dermal 
APCs.
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INTRODUCTION 
 
Psoriasis is a chronic autoimmune skin disorder believed to be mediated by pathogenic 
interactions between dendritic cells (DCs), T cells and keratinocytes (Lowes et al., 2007). 
Several DC subsets have been shown to accumulate in psoriatic skin and, as efficient 
antigen presenting cells (APCs), they are thought to stimulate pathogenic T cells locally 
(Lowes et al., 2007;Nickoloff et al., 2007). This concept is underscored by the fact that 
several new biologics with clinical effect in psoriasis specifically target molecules 
involved in DC-T-cell interactions (Tzu and Kerdel, 2008).   
Plasmacytoid (p)DCs are present in very low numbers in normal skin (Zaba et al., 
2009b) but recent reports have shown that pDC numbers are increased in psoriatic 
lesions and contribute to immune pathology, mainly through the production of interferon 
(IFN)- (Nestle et al., 2005;Yao et al., 2008). Interestingly, a recent publication 
demonstrated that pDCs are activated through toll-like receptor (TLR) 9 via endogenous 
DNA coupled with the antimicrobial peptide LL37, which is upregulated in psoriasis 
(Lande et al., 2007).  
 Under steady-state conditions human dermal myeloid APCs have been found to 
consist of functionally and phenotypically distinct populations of myeloid (m)DCs and 
macrophages (Zaba et al., 2007b). Resident dermal mDCs are characterized by the 
expression of CD11c and CD1c (Zaba et al., 2009b). Dermal macrophages are usually 
CD11c- but express CD163 (Zaba et al., 2007b). Although the C-type lectin DC-specific 
integrin ICAM-3 grabbing non-integrin (DC-SIGN, CD209) was previously believed to 
be a specific marker for DCs, it has more recently been found to be expressed primarily 
on macrophages in normal skin (Ochoa et al., 2008) as well as in other tissues (Raki et 
al., 2006).  
In psoriatic lesions an additional mDC subtype expressing CD11c but not CD1c 
has been identified (Zaba et al., 2009b). These cells have been termed inflammatory 
DCs, and a proportion of these, but not the CD11c+CD1c+ resident subset, also expresses 
the monocyte/macrophage markers CD163, DC-SIGN and CD14 (Zaba et al., 2009a). 
Moreover, these inflammatory dermal mDCs were shown to produce TNF-, inducible 
nitric oxide synthase (iNOS), interleukin (IL)-23, and to activate both Th1 and Th17 T 
cells and could therefore potentially be central players in psoriasis pathogenesis (Zaba et 
al., 2009a).  
 3
In addition to pDCs and inflammatory mDCs, macrophages have also been 
implicated in psoriasis pathogenesis. They were shown to be a source of pathogenic 
TNF- in mouse models of the disease (Stratis et al., 2006;Wang et al., 2006) and there 
is evidence to suggest that macrophages contribute to psoriasis also in humans (Marble et 
al., 2007;Wang et al., 2009a). 
We have recently shown that significant clinical improvement during 16 days of sun 
exposure was associated with rapid reduction in T-cell numbers in lesional skin as well 
as downregulation of inflammatory parameters both in situ and systemically (Søyland et
al, manuscript accepted in BJD, pending revision). Here, we further analyze the same 
patient material, and show that 16 days of sun exposure induces rapid reduction in IFN-
-producing pDCs , CD11c+CD1c- dermal inflammatory DCs as well  as well as 
macrophages in psoriatic skin.  
 
 
RESULTS 
 
20 patients with psoriasis were enrolled in a study to examine the immunological impact 
of heliotherapy in psoriatic patients. Clinical and histological data are described in detail 
elsewhere (Søyland et al., manuscript accepted in BJD, pending revision). Skin biopsies 
were obtained from 5 randomly selected patients with moderate to severe psoriasis 
undergoing 16 days of controlled sun exposure in Gran Canaria in the month of March. 
Specimens were obtained from lesional and non-lesional skin at day 0, day 2 and day 16. 
All 20 patients experienced clinical improvement with significant reduction in PASI-
score during the study period of 16 days. Figure 1 shows PASI-scores for the 5 patients 
described here. Moreover, epidermal thickening in lesional skin, examined by H+E 
staining, was significantly reduced in all patients, as described elsewhere (Søyland et al., 
manuscript accepted in BJD, pending revision).  
 
pDCs and the IFN- -inducible protein MxA are reduced in lesional dermis after 
sun exposure 
The density of dermal pDCs, defined as cells coexpressing the surface markers CD123 
and CD45RA (Figure 2a-e), was markedly higher in lesional compared with non-lesional 
skin before sun treatment (median 80 vs 2 cells per mm2). 16 days of sun exposure led to 
a significant reduction in the density of pDCs in lesional skin (P<0.05; Figure 2a, c and 
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d), whereas a small but significant increase (P<0.05; Figure 2b) was observed in non-
lesional skin.  
It has been demonstrated that production of IFN- by pDCs contributes to the 
pathology of psoriasis (Nestle et al., 2005). We examined formalin-fixed specimens 
obtained at baseline and day 16 from 5 different patients for the expression of MxA, a 
well established surrogate marker for IFN- (Farkas et al., 2001;Fah et al., 1995;Simon
et al., 1991). Importantly, we found that whereas MxA was undetectable in non-lesional 
skin both before and after sun treatment, epidermal expression of MxA was strongly 
upregulated in lesional epidermis with marked reduction in all patients after sun exposure 
(Figure 2f-i).  
 Together, these findings indicated that 16 days of sun exposure significantly 
lowered the number of pDCs in the lesion coinciding with evidence of reduced IFN- 
production.  
 
CD11c+CD1c- inflammatory DCs are selectively reduced in lesional dermis after sun 
exposure  
Total numbers of dermal CD11c+ DCs were markedly increased in lesional 
compared with non-lesional skin (Supplemental Figure 1). In agreement with previous 
reports (Lowes et al., 2008) we found that this increase was mainly due to a 20-fold  
increase in the putative inflammatory CD11c+CD1c- subset (Fig 3a, c, e and g), of which 
a substantial fraction coexpressed CD163, DC-SIGN and CD14 (Figures 4a-c and 5a-c). 
In contrast, the “resident” dermal CD11c+CD1c+ DC population was only 2-fold 
increased (Figure 3b, d, e and g). These cells did not express CD163 or DC-SIGN, either 
in lesional (Figure 6a and b) or in non-lesional dermis (Figure 6c and d). The percentage 
of CD11c+ DCs expressing the maturation marker DC-LAMP was 2-fold increased in 
lesional compared with non-lesional skin (Figure 7a-e). As also found by others (Zaba et 
al., 2009a) DC-LAMP+ cells were mainly located in dermal cellular aggregates, in which 
most, but not all coexpressed CD1c (Figure 7f). 
After 16 days of sun exposure, the CD11c+CD1c- DC population in lesional dermis 
was significantly decreased (P<0.05; Figure 3a, e-f), with marked reduction in cell 
numbers evident already at day 2, whereas the number of dermal CD11c+CD1c+ DCs 
was unchanged (Figure 3b). The percentage of CD11c+ DCs coexpressing DC-LAMP in 
lesional dermis was also significantly reduced (P<0.05) after sun exposure (Figure 7a, c-
d).  
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As mentioned above, a substantial fraction of CD11c+CD1c- DCs expressed 
monocyte/macrophage markers. The number of CD11c+CD1c- DCs coexpressing DC-
SIGN decreased (P<0.05; Figure 4b) in response to 16 days of sun exposure, whereas the 
fractions expressing CD163 or CD14 were unchanged (Figure 4a and c).   
Although only minor changes in cell densities were observed for the CD11c+ DC 
subsets in non-lesional skin (Figure 3c and d), small but significant increases in total 
CD11c+ cells (Supplemental figure 1b) as well as CD11c+CD1c- DCs coexpressing 
CD163, DC-SIGN and CD14 were observed (Figure 4d-f).   
Together our findings demonstrated that sun treatment led to a significant reduction 
of putative inflammatory mDCs as well as a decrease in mature DCs, indicating that a 
situation more resembling a homeostatic condition was established.  
 
Dermal macrophages are reduced after sun exposure 
Differential expression of CD11c and CD163 has been shown to distinguish DCs from 
macrophages under steady-state conditions (Zaba et al., 2007b).  Accordingly, we found 
that nearly all  CD163+ cells in non-lesional skin were negative for CD11c (Figure 4d, 5e 
and 8d), but expressed DC-SIGN (Figure 5d). A substantial proportion also expressed 
CD14 (data not shown).  In lesional skin a large proportion of putative inflammatory 
DCs coexpressed several macrophage markers as described above. We therefore defined 
dermal macrophages as CD11c-CD163+ cells. This population was approximately 2-fold 
increased in lesional skin but returned to non-lesional levels after sun treatment (Figure 
8a). Also the numbers of CD11c-DC-SIGN+ cells were significantly reduced in lesional 
dermis after sun exposure (P<0.05; Figure 8b), whereas no significant change in CD11c-
CD14+ cell numbers was observed (Figure 8c).  Together, this finding demonstrated that 
dermal macrophages were also significantly affected by sun treatment. 
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DISCUSSION 
 
It is well documented that UV therapy has beneficial effects in various immune-
mediated skin disorders. This effect is believed to be mediated by UV-induced 
immunosuppression (Ullrich, 2005;Schwarz, 2005). Among cutaneous DCs, epidermal 
LCs is the best studied subset with respect to the immunosuppressive effect of UV 
therapy (Ullrich, 2005). However recently, it was shown in a mouse model of contact 
hypersensitivity that dermal DCs was essential for UV-induced suppression in the 
absence of LCs (Wang et al., 2009b). We demonstrated here that distinct populations of 
dermal DCs were dramatically reduced in psoriatic lesions after 16 days of controlled sun 
exposure.  In contrast, we recently found that the number of lesional LCs was only 
marginally affected examining the same tissue material (Søyland et al., manuscript 
accepted in BJD, pending revision).  
Others have shown that inflammatory CD11c+CD1c- DCs accumulate in psoriatic 
lesions and drive the inflammatory process by producing IL-23, iNOS, and TNF- 
(Lowes et al., 2005;Zaba et al., 2009a). As expected, we also found that CD11c+CD1c- 
DCs were dramatically increased (20-fold) in lesional skin, and importantly, the number 
of these cells decreased significantly after 16 days of sun exposure. Moreover, this 
decrease concurred with reduced mRNA expression for IL-23 (Søyland et al., manuscript 
accepted in BJD, pending revision). Already after two days we observed reduced 
numbers of CD11c+CD1c- DCs, which preceded the clinical improvement. The density of 
“resident” dermal CD11c+CD1c+ DCs was unaffected by sun exposure, but the 
expression of the maturation marker DC-LAMP, primarily found on the CD11c+CD1c+ 
population, was reduced. Our results therefore suggest that sun treatment selectively 
inhibit accumulation of the inflammatory myeloid subset, allowing the reestablishment of 
homeostasis by normalizing the balance and maturation status of dermal myeloid DCs. 
Recent reports have suggested that accumulating IFN--producing pDCs also play a 
pivotal role in psoriasis. IFN- has diverse downstream effects, among which are 
activation of mDCs (Gilliet et al., 2008).We also found that accumulation of  pDCs in 
lesional skin was associated with increased expression of MxA, a protein selectively 
induced by IFN-. Importantly, both the number of pDCs and expression of MxA were 
dramatically reduced in response to sun exposure. To our knowledge, the effect of UV 
exposure on pDCs has not been examined previously.  
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The current view of psoriasis immunopathogenesis suggests an intimate crosstalk 
between stressed keratinocytes, activated pDCs and mDCs, and pathogenic T cells 
(Lowes et al., 2007). Here and in a separate report (Søyland et al., manuscript accepted in 
BJD, pending revision) we show that 16 days of sun exposure has a significant favorable 
effect on both keratinocytes, measured by reduction in epidermal thickness, T cells, and 
dermal DCs. However, whether reduction in the number and activation state of pDCs and 
inflammatory mDCs was mainly a direct effect of sun treatment or mediated through the 
effect on other cells (e.g. T cells and/or keratinocytes) could not be determined in this 
study. Regulatory T cells are induced by UV therapy (Schwarz et al., 2007). We found a 
relative increase in the number of FOXP3+ T cells and IL-10 production after treatment 
(Søyland et al., manuscript accepted in BJD, pending revision) indicating that this 
immunomodulatory cytokine, produced by regulatory T cells or other cell types could 
play a role.  
There is evidence that macrophages contribute to psoriasis in humans (Marble et al., 
2007;Wang et al., 2009a). Here, we showed that although single positive CD11c-CD163+ 
and CD11c-DC-SIGN+ macrophages were only 2-fold increased in lesional dermis, these 
cells were significantly reduced in lesional skin upon sun exposure, suggesting that 
dermal macrophages may also play a role in this disease.  
The psoriatic lesion was dominated by CD11c+CD1c- DCs coexpressing the 
monocyte/macrophage markers CD14, CD163 and DC-SIGN. Recent reports have 
demonstrated that circulating monocytes are an important source for DCs in peripheral 
tissues (Auffray et al., 2009). Our phenotypic characterization of inflammatory DCs in 
psoriatic skin is compatible with this concept. However, the finding that there was a 
dramatic reduction in the CD11c+CD1c- DC population after sun exposure, but no similar 
decrease in the CD11c+ subset that coexpressed CD163 and CD14 could imply that the 
CD11c+CD1c- DCs represents a distinct subgroup. However, monocytes, macrophages 
and DCs all show high degree of plasticity and their phenotype and function depend on 
the local microenvironment (Auffray et al., 2009). Therefore, further studies are needed 
to define the origin and differentiation pathways of dermal APC populations both under 
steady state and during inflammation. 
Biological agents have received much attention in the treatment of severe psoriasis. 
Recently, it was shown that etanercept (TNF receptor-immunoglobulin fusion protein) 
had a significant effect on psoriasis by inhibiting the activity of dermal DCs (Zaba et al., 
2007a). Importantly, we show here, and in a separate report (Søyland et al), that sun 
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treatment has at least comparable effect with two weeks of etanercept treatment based on 
the reduction of PASI-score, epidermal thickness, CD11c+ DCs, CD163+ macrophages, 
CD3+ T cells, MxA expression, DC-LAMP expression and IL-23 mRNA. 
In conclusion, this study demonstrates that sun exposure results in rapid reductions in 
pathogenic DC subsets as well as macrophages in psoriatic lesional dermis, thus restoring 
conditions associated with homeostasis. These changes took place preceding clinical 
improvement, suggesting that UV-induced immunosuppression is mediated, at least in 
part, through an effect on dermal APCs and their products.   
 
 
MATERIALS AND METHODS 
 
Study population.  
A total of 20 patients (mean/median age 47.2/48 years, range 24-65, 6 females and 14 
males) were enrolled in the study and transported from Norway to Gran Canary, Spain, in 
the month of March. The patients were evaluated by the same dermatologist for the 
Psoriatic Area and Severity Index (PASI) (Fredriksson and Pettersson, 1978) before and 
after heliotherapy. All patients had moderate to severe plaque psoriasis, i.e. mean/median 
PASI before sun exposure of 9.8/8.7, range 3.8-18.8. All patients had stopped using any 
psoriasis medication at least 4 weeks prior to this study. Two of the patients had skin 
type II and 18 had skin type III according to the Fitzpatrick classification (Fitzpatrick, 
1988). 
UV was measured every hour from 9 a.m. to 5 p.m. using broadband UVB and UVA 
plus narrowband 311 nm broadband CIE-weighted UVB and spectral UVA-detectors as 
described elsewhere (Nilsen et al., 2009) 
The study was approved by the Regional Committee of Medical Ethics and all 
patients gave their written, informed consent.  
Clinical data for all 20 patients are presented elsewhere (Søyland et al., manuscript 
accepted in BJD, pending revision). 
 
Skin biopsies  
4 mm punch biopsy specimens from lesional and non-lesional skin from 5 patients on 
days 0 (baseline), 2 and 16 and from another 5 patients on day 0 and 16 (used here for 
MxA detection). The samples from each individual patient were obtained within the 
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same body area on all days but in sufficient distance to avoid reactive inflammation from 
prior biopsy sampling. Specimens were either snap frozen in liquid nitrogen and stored at 
-70 or fixed in formalin and thereafter embedded in paraffin.  
 
Immunohistochemistry 
Frozen sections were cut at 4 m and fixed in acetone prior to staining. Two-colour 
immunofluorescence staining was performed as detailed elsewhere (Søyland et al., 
manuscript accepted in BJD, pending revision). The panel of antibodies and reagents 
used are given in Table S1.  
MxA staining was performed on formalin-fixed and paraffin-embedded specimens, 
because this antibody does not work on frozen sections. Details are described elsewhere 
(Farkas et al., 2001).  
Stained sections were examined blindly by fluorescence microscopy at x 400 
magnification by the same investigator (IH). An ocular grid was used and all positive 
immunostained cells in the dermis to a depth of 250 μm below the the rete ridges. Cell 
counts were given as total number per square millimetre. MxA staining of the epithelium 
was estimated on an arbitrary scale from 0 to 5. 
 
Statistics 
Non-parametric Friedman test with Dunn’s multiple comparison post-test was performed 
to compare cell counts obtained from 5 different patients at three different time-points. 
Student’s t-test was used for analysis of PASI-score. P<0.05 was interpreted as 
significant.  
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FIGURE LEGENDS 
 
Figure 1. PASI scores were significantly reduced in patients after 16 days of sun 
exposure.   
All 5 patients included in this study showed excellent clinical improvement after 16 days 
of sun exposure with significant reductions in PASI-scores (Student’s t-test). 
 
 
Figure 2. The numbers of pDCs and IFN- expression in lesional skin were reduced by 
sun exposure.  
The number of pDCs, defined as cells expressing both CD123 (red images) and CD45RA 
(green images), was markedly increased in lesional compared with non-lesional dermis (a 
and b) and was significantly reduced in lesional dermis after 16 days of sun exposure (a, c 
and d). In contrast, a significant increase in pDCs was seen in non-lesional skin after sun 
exposure. Note that the anti-CD123 antibody (red) stains endothelial cells (d-f).  
In non-lesional skin, expression of MxA, a surrogate marker for IFN- expression, was 
markedly upregulated in lesional skin whereas it was undetectable in non-lesional skin (f, 
g and i). After 16 days of sun exposure, MxA expression was markedly reduced in 
lesional skin (f and h) The increase in pDC numbers after sun exposure in non-lesional 
skin was not paralleled by an increase in MxA-staining (b and f). All images are at x200 
magnification. Bars=25 μm 
 
 
Figure 3.  CD11c+ CD1c-DC populations lesional dermis are rapidly and selectively 
reduced upon sun exposure  
The putative inflammatory CD11c+CD1c- DCs were 20-fold increased at baseline in 
lesional dermis (a) compared with non-lesional (c). This cell population was significantly 
reduced at day 16 of sun exposure with marked reductions evident already at day 2 (a, e and 
f). CD11c+CD1c+ DCs, i.e. putative homeostatic DCs were only 2-fold increased in lesional 
dermis and were unchanged after sun exposure (b, e and f). In non-lesional dermis only 
very few CD11c+CD1c- cells were found at baseline (c and g). No significant changes in 
CD11c+CD1c- or CD1c+ DCs were seen in lesional dermis after sun exposure (c and d). 
Images are at x200 magnification. Bars=25 μm 
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Figure 4. In lesional dermis a substantial fraction of CD11c+ DCs coexpress the 
monocyte/macrophage markers CD163, DC-SIGN and CD14. The number of CD11c+ 
DCs coexpressing the monocyte/macrophage markers CD163 (a), DC-SIGN (b) and CD14 
(c) were markedly higher in lesional than in non-lesional dermis where only very few 
double positive cells could be found (d-f). Only the number of CD11c+DC-SIGN+ cells was 
significantly reduced after 16 days of sun exposure (b). In non-lesional dermis sun exposure 
induced small but significant increases in all these three subsets (d-f).  
 
 
Figure 5. CD11c+ DCs in lesional skin coexpress monocyte/macrophage markers. 
Immunohistochemical staining shows the infiltration of CD11c+ cells (green images) 
coexpressing the monocyte/macrophage markers CD163 (a), DC-SIGN (b) and CD14 (c) 
(all red images). In non-lesional dermis only occasional CD11c+ DCs coexpressed CD163 
(e), DC-SIGN (f) or CD14 (g). DC-SIGN was primarily expressed on CD163+ cells in both 
lesional (d) and non-lesional skin (h). Images are at x400 magnification. Bars=50μm 
 
 
Figure 6. CD1c+ DCs did not express CD163 or DC-SIGN  
CD1c+ DCs (red images) accumulate in dermal cellular aggregates in lesional dermis (a and 
b). No CD1c+ DCs  coexpressed CD163 or DC-SIGN at baseline in lesional dermis (a and 
b) or non-lesional (c and d). Images are at x400 magnification. Bars=50μm 
 
 
Figure 7. Expression of DC maturation marker DC-LAMP (CD208) was reduced in 
bothlesional and non-lesional dermis after sun exposure  
The percentage of dermal CD11c+ cells (green images) that coexpressed the maturation 
marker DC-LAMP (red images) was approximately 2-fold increased in lesional skin (a and 
c) compared with non-lesional (b and e) at baseline. After 16 days of sun exposure 
significant reductions in this percentage was seen in both lesional (a and c) and non-lesional 
dermis (b). DC-LAMP+ cells (f, green image) accumulated in dermal cellular aggregates, 
with CD1c+ cells (f, red image) and most, but not all DC-LAMP+ cells were CD1c+ (f). 
Images (c-e) are at x200 magnification, bars=25μm. Image (f) is at x400 magnification, 
bar=50μm 
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Figure 8. The numbers CD11c-CD163+ and CD11c-DC-SIGN+ macrophages were 
significantly reduced in lesional dermis after sun exposure. In lesional dermis single 
positive (i.e. CD11c-) CD163+ (a) and DC-SIGN+ macrophages (b) were approximately 2-
fold increased compared with non-lesional dermis (d and e) and significantly reduced in 
after sun exposure. Single positive CD14+ cells (c) were also 2-fold increased in lesional 
dermis compared with non-lesional (f) with no significant change upon sun exposure. No 
significant changes in any of these cell subsets were observed in non-lesional dermis (d-f). 
 
 
 
Supplemental Figure 1. The total number of CD11c+ DCs was unchanged in lesional 
dermis after sun exposure. The total number of CD11c+ cells was markedly increased in 
lesional (a) compared with non-lesional dermis (b). In lesional dermis, numbers were 
reduced in all individuals but the change was non-significant (a). In non-lesional dermis a 
small but significant increase in total CD11c+ numbers was seen at day 16 of sun exposure 
(b). 
 
Supplemental Table 1. List of primary and secondary antibodies and reagents with 
manufacturers used in this paper. 
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Table S1
Primary antibodies
Antibody 
specificity Clone Isotype Manufacturer
HLA-DR L243 IgG2a BD Immunocytometry Syst., San Jose, CA
CD11c CBR-p150/4G1 IgG2a Biosource, Camarillo, CA
CD11c KB90 IgG1 Gift from Dr. Pulford, Oxford
CD1c M241 IgG1 Ancell, Bayport, MN
CD163 RM3/1 IgG1 Affinity Bioreagents, Golden, CO
CD163 GHI/61
IgG1-
biotin BioLegend, San Diego, CA
DC-SIGN (CD209) 516.111 IgG2a Gift from Dr. Westin, Oslo, Norway
DC-SIGN (CD209) 531.111 IgG1 Gift from Dr. Westin, Oslo, Norway
CD14 RM052 IgG2a Biosys, Compiegne, France
DC-LAMP (CD208) 104G4 IgG1 Immunotech, Marseille, FR
DC-LAMP (CD208) 104G4
IgG1-
biotin Nordic Biosite, Täby, Sweden
CD45RA L48 IgG1 BD Immunocytometry Syst., San Jose, CA
CD123 7G3 IgG2a BD Pharmingen, San Diego, CA
MxA M143 IgG2a Gift from Dr. Haller, Freiburg, Germany
Secondary antibodies
Antibody 
specificity Origin Labelling Manufacturer
Mouse IgG1 Goat Cy3 Southern Biotech, Birmingham, AL
Mouse IgG2a Goat biotin Southern Biotech, Birmingham, AL
Mouse IgG (H+L) Goat Cy3 Jackson Immunoresearch, West Grove, PA
Mouse IgG1 Goat biotin Southern Biotech, Birmingham, AL
Mouse IgG2a Goat Cy3 Southern Biotech, Birmingham, AL
Streptavidin Cy2 Amersham Biosciences, Little Chalfont, UK
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Errata:
The following changes have been made in the manuscript Paper II since the thesis was 
originally submitted for evaluation. The doctoral committee has granted permission for 
the changes to be implemented in the current printed version. 
Page 6, line 15: deleted “not shown”. 
Page 7, line 5: inserted “(Figures 4B and C)” 
Page 7, line 10: “5A” replaced by “4C” 
Page 7, line 20: “5B” replaced by “5” 
Page 7 line 22: “5B” replaced by “5” 
Page 2, abstract, line 11: ”mm” replaced by “cm” 
Page 6, line 27: ”mm” replaced by “cm” 
Page 8, line 32: ”mm” replaced by “cm” 
Page 9, line 2: ”mm” replaced by “cm” 
